    
 
A STUDY OF THE SAFETY AND ACCEPTABILITY OF A PLACEBO VAGINAL FILM:  
FAME 101  
 
DAIDS -ES # [ZIP_CODE]  
 
 
Funding Agency:  
Division of AIDS, US National Institute of Allergy and Infectious Diseases  
US National Institutes of Health  
 
Grant Number: 1U19 AI120249  
 
Protocol Chair:  
Katherine Bunge, MD MPH  
University of Pi[INVESTIGATOR_219356], PA [LOCATION_003]  
 
 
Protocol Co -Chair  
Sharon Hillier, PhD  
University of Pi[INVESTIGATOR_219356], PA [LOCATION_003]  
 
 
Study Site:  
Magee -Womens Hospi[INVESTIGATOR_280921], PA  
Phone:  412 -641-6435  
Fax:  412 -641-1133  
 
20September2017  
Version  1.0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FAME -101 version 1.0 20September2017   Page 2 A study of the safety and acceptability of a placebo vaginal film:  
 FAME [ADDRESS_342700] OF ABBREVIA TIONS AND ACRONYMS  ................................ ................................ .........  5 
PROTOCOL TEAM ROSTER  ................................ ................................ ................................ .... 6 
PROTOCOL SUMMARY  ................................ ................................ ................................ ...........  8 
1 KEY ROLES  ................................ ................................ ................................ ..................... 10 
1.1 Protocol Identification  ................................ ................................ ......................  10 
1.2 Funding  ................................ ................................ ................................ ...........  10 
1.3 Monitor Identification  ................................ ................................ .......................  10 
1.4 Protocol Chair  ................................ ................................ ................................ . 10 
1.5 Laboratory  ................................ ................................ ................................ ....... 10 
2 INTRODUCTION  ................................ ................................ ................................ ............... 12 
2.1 HIV prevention and microbicides  ................................ ................................ .... 12 
2.2 Integrated Preclinical/Clinical Program  ................................ ...........................  12 
2.3 Rationale  ................................ ................................ ................................ .........  13 
2.4 Safety Data: Placebo Film ................................ ................................ ...............  [ADDRESS_342701] Dispensing  ................................ ................................ ...............  19 
6.6 Concomitant Medications  ................................ ................................ ................  19 
7 STUDY PROCEDURES  ................................ ................................ ................................ ....19 
7.1 Pre-Screening  ................................ ................................ ................................ . 19 
7.2 Visit 1: Screening Visit  ................................ ................................ ....................  19 
7.3 Visit 2: Enrollment  ................................ ................................ ...........................  20 
7.4 Visit 3: Follow -Up Visit  ................................ ................................ ....................  22 
7.5 Visit 4: Follow -Up Visit [ADDRESS_342702] Hold  ................................ ................................ ................................ ................  29 
8.6 Criteria for Early Termination of Study Participation  ................................ ....... 29 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ .................. 30 
9.1 Review of Study Design  ................................ ................................ ..................  30 
9.2 Sample Size and Accrual  ................................ ................................ ................  30 
9.3 Study Endpoints  ................................ ................................ ..............................  31 
9.3.1 Primary Endpoint  ................................ ................................ ................................ .........  31 
9.3.2 Secondary Endpoints  ................................ ................................ ................................ ... 31 
9.4 Blinding  ................................ ................................ ................................ ...........  32 
9.5 Random Assignment  ................................ ................................ .......................  32 
9.6 Data Monitoring and Analysis  ................................ ................................ .........  32 
9.6.1 Data Monitoring  ................................ ................................ ................................ ...........  32 
9.6.2 Primary Endpoint Analysis  ................................ ................................ ..........................  32 
9.6.3 Secondary Endpoint Analysis  ................................ ................................ ......................  32 
9.6.4 Analysis Cohort  ................................ ................................ ................................ ...........  33 
10 HUMAN SUBJECTS CONSIDERATIONS  ................................ ................................ ........ 34 
10.1  Special Populations  ................................ ................................ ........................  34 
10.1.1 Men  ................................ ................................ ................................ ............................  34 
10.1.2 Children ................................ ................................ ................................ ......................  34 
10.1.3 Prisoners  ................................ ................................ ................................ .....................  34 
10.1.4 Pregnant women ................................ ................................ ................................ .........  34 
10.2  Informed Consent Process ................................ ................................ ..............  35 
10.2.1 Risk/Bene fit Statement  ................................ ................................ ..............................  [ADDRESS_342703] Containment  ................................ ................................ ..................  38 
12 ADMINISTRATIVE PROCEDURES  ................................ ................................ .................. 38 
FAME -101 version 1.0 20September2017   Page 4 12.1  Protocol Registration  ................................ ................................ .......................  38 
12.2  Study Coordination  ................................ ................................ .........................  39 
12.3  Study Monitoring  ................................ ................................ .............................  39 
12.4  Protocol Compliance  ................................ ................................ .......................  39 
12.5  Investigator’s Records  ................................ ................................ ....................  39 
12.6  Use of Information and Publications  ................................ ...............................  40 
12.7  Training Procedures  ................................ ................................ ........................  40 
REFERENCES  ................................ ................................ ................................ ......................... 41 
APPENDIX I:  SCHEDULE OF STUDY VISITS AND PROCEDURES  .........  Error! Bookmark not 
defined.  
APPENDIX II:  HIV TESTING AGORITHIM  ................................ ................................ .............. 43 
APPENDIX III: SAMPLE INFORMED CONSENT  ................................ ................................ .....44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FAME -101 version 1.0 20September2017   Page 5 A study of the safety and acceptability of a placebo vaginal film:  
 FAME [ADDRESS_342704] operating procedure(s)  
STI   Sexually transmitted infection  
FAME -101 version 1.0 20September2017   Page 6 A study of the safety and acceptability of a placebo vaginal film:  
 FAME [ADDRESS_342705]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-6967  
Fax: 412 -641-1133  
Email: [EMAIL_4599]   
 
Sharon Hillier, PhD  
Protocol Co -Chair  
Department of Obstetrics,  
Gynecology and Reproductive Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_342706]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-8933  
Fax: 412 -641-6170  
Email: [EMAIL_5476]  
 
Lisa Rohan, PhD  
Co-investigator  
Department of Pharmaceutical Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_342707]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
Phone: 412 -641-6108  
Fax: 1 2-641-6170  
Email:  [EMAIL_5477]  
 
Charlene S. Dezzutti, PhD  
Co-investigator  
Department of Obstetrics,  
Gynecology and Reproductive Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_342708]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-3462  
Fax: 412 -641-6170  
Email: [EMAIL_5478]  
 
 
 
 
 
 
 Bernard Moncla, PhD  
Co-investigator  
Department of Obstetrics, Gynecology and 
Reproductive Sciences  
Magee -Womens Research Institute  
[ADDRESS_342709]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
Phone: 412 -641-6025  
Fax: 412 -641-6170  
Email:  [EMAIL_5479]  
 
Leslie Meyn, PhD  
Biostatistician/Epi[INVESTIGATOR_280922],  
Gynecology and Reproducti ve Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_342710]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
Phone:  42 -641-4233  
Fax: 412 -641-1133  
Email:  [EMAIL_5480]   
 
Lara K. Mahal, PhD  
Co-investigator  
Department of Chemistry  
[LOCATION_001] University  
[ADDRESS_342711]  Room 1001  
[LOCATION_001], NY [ZIP_CODE]  
Phone:  212 -998-3533  
Fax:  212 -995-4475  
Email:  [EMAIL_5481]  
 
Peter L. Anderson, PharmD  
Co-investigator  
Department of Pharmaceutical Sciences  
Skaggs School of Pharmacy and Pharmaceutical 
Sciences  
University of  Colorado Anschutz Medical Campus  
V20-C238, Room [ADDRESS_342712].  
Aurora, CO [ZIP_CODE]  
Phone:  303 -724-6128  
Fax:  303 -724-6135  
Email:  [EMAIL_1651]  
 
 
 
 
 
FAME -101 version 1.0 20September2017   Page 7 Julie S. Downs, PhD  
Co-investigator  
Dept. of Social and Decision Sciences  
Carnegie Mellon University  
208 Porter Hall  (SDS)  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] -3890  
Office:  219 -C Porter Hall  
Phone:  412 -268-1862  
Fax:  412 -268-6938  
Email:  [EMAIL_5482]  
 
NIH 
Hans M.L. Spi[INVESTIGATOR_16614], MD  
Sr. Medical Officer, PMPRB/Prevention 
Sciences Program,  
Contractor, Kelly Government Solutions  
DAIDS, NIAI D, NIH  
[ADDRESS_342713]  
Room 8B51A  
Rockville, MD [ZIP_CODE]  
Tel:  [PHONE_5830]  
Fax: 240 -627-3465  
Email: [EMAIL_5483]  
 
 
 Jim A. Turpin, PhD   
Branch Chief  
Preclinical Microbicides and Prevention Resea rch 
Branch (PMPRB)  
NIAID/DAIDS  
Room 8B31/MSC [ADDRESS_342714]  
Rockville, MD [ZIP_CODE] -9831  
Phone    (301) 451 -2732  
Fax (240) 627 -3465  
Email: [EMAIL_5484]   
 
 
Cherlynn Mathias, RN, BSN  
Program Officer/ Nurse Consultant  
Prevention Science Program, NIH/DAIDS/PSP  
[ADDRESS_342715], 8B51B MSC 9831  
Rockville, MD [ZIP_CODE]  
Phone:  [PHONE_5831]  
Fax: 240 -627-3465  
Email:  [EMAIL_5485]   
 
Jeanna Pi[INVESTIGATOR_11826], MD  
Sr. Medica l Officer  
Clinical Microbicide Research Branch  
PSP/DAIDS/NIAID/NIH  
[ADDRESS_342716]  
Room 8B68  
Rockville, MD [ZIP_CODE]  
Tel: 240 -292-4798  
E-mail: [EMAIL_5486]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FAME -101 version 1.0 20September2017   Page 8 A study of the safety and acceptability of a placebo vaginal film:  
 FAME  101  
PROTOCOL SUMMARY  
 
Short Title:         FAME 101  
 
Protocol Chair : Katherine  Bunge, MD MPH   
 
Protocol Co -chair:  Sharon Hillier, PhD  
 
Sample Size:  Approximately  64  
 
Study Population:   HIV-uninfected women , 18 – 45 years old  
 
Study Sites:  Magee -Womens  Hospi[INVESTIGATOR_280923] , Pi[INVESTIGATOR_9109], PA   
 
Study Design:  A phase I, 4 arm, single site, open label placebo trial with 
random ization to  timing of follow -up 
 
 
 
 
 
 
 
 
 
 
 
 
Study Duration:  Accrual of approximately [ADDRESS_342717] ed duration of study participation for ea ch participant  will be 
approximately 5 to 1 1 weeks.  This includes the screening period.  After 
enrollment, the study duration is 3 weeks.  
 
 Study Products:  Vaginal  Film 
   One dose p lacebo vaginal film (2” x 2” size)  
 
     
Study Regimen:  All participants will receive a single dose of vaginal placebo film that will 
be self -administered   
 
 
Primary Objective : 
 
• To assess the safety of a single dose of a  placebo film which is intended for extended 
release of antiretroviral  drugs . 
 
Primary Endpoint : 
 
• Grade 2 or higher Adverse Events  
 
 Visit 1  Visit 2  Visit 3   Visit 4    
____________ ______________________________________ _____  
-45 days  Day 0              Day 3,7,10 or 14 * Day 21 
 
*Randomized to  timing of Visit 3   
FAME -101 version 1.0 20September2017   Page 9 Secondary Objectives:  
 
• Acceptability  
 
o To describe the acceptability of the placebo vaginal film and identify qualities 
associated with higher or lower degrees of acceptability  
 
Secondary Endpoi nt: 
 
• Acceptability  
 
o Self-reported assessment of qualities of the experience with the film drawn from 
existing survey on microbicidal films, and general acceptability ratings drawn from 
market  research methodology  
 
 
Exploratory Objectives:  
 
 
• Vaginal Microen vironment  
 
o  To compare the effects of the placebo film on the vaginal microbiota and glycome 
pre and post study product use  
 
 
• Persistence  
 
o To describe the persistence of the film at 3,7,10 and 14  days after insertion  
 
Exploratory Endpoints:  
 
• Vaginal Microenvironment  
 
o Cervicovaginal lavage (CVL)  
o Levels of anti -viral activity  
o Lectin microarray  
o Levels of glycoproteins and mucins  
o Levels of cytokine and innate immunity factors  
 
o Vaginal    
o Quantitative vaginal cultures  and quantitative PCR for selected micro biota  
o Nugent score  
 
 
• Persistence  
 
o  Eudragit ®levels in CVL  
FAME -101 version 1.0 20September2017   Page 10  
1 KEY ROLES  
 
1.1 Protocol Identification  
Protocol Title:  A study of the safety and acceptability of a placebo vaginal film:  
 
Short Title:  FAME 101  
  
Date:   September 20 , 2017   
 
1.2 Funding  
Funding Agency : DAIDS/NIAID/NIH  
              [ADDRESS_342718]  
                                   Rockville, MD [ZIP_CODE] -9831  
 
 
1.3 Monitor Identification  
Monitor:   Pharmaceutical Product Development  ([COMPANY_003]) , Inc.  
   [ADDRESS_342719]  
Wilmington, NC [ZIP_CODE] -3331 [LOCATION_003]  
   
1.4 Proto col Chair  
Protocol Chair:  Katherine Bunge, MD MPH  
Department of Obstetrics,  
Gynecology and Reproductive Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_342720]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-6967  
Fax: 412 -641-1133  
Email: [EMAIL_4599]   
 
 
Protocol Co-Chair:  Sharon L. Hillier, PhD  
   University of Pi[INVESTIGATOR_280924] -Womens Hospi[INVESTIGATOR_307]  
   [ADDRESS_342721]  
   Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
   Phone: 412 -641-6435  
   Fax: 412 -641-1133  
   Email:  [EMAIL_5476]  
  
1.5 Laboratory  
Safety Labs : Magee -Womens  Hospi[INVESTIGATOR_117813]  
  [ADDRESS_342722]  
  Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
 
FAME -101 version 1.0 20September2017   Page 11 Pharmacology : Anderson Laboratory  
   [ZIP_CODE] E. Montview Bl vd.  
Aurora, CO [ZIP_CODE]  
 
Anti-viral 
Studies:  Dezzutti Laboratory  
  [ADDRESS_342723]  
  Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
 
Microbiology  
Studies:  Hillier Laboratory  
  [ADDRESS_342724]  
  Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
 
 
Glycome  Moncla Laboratory  
Studies:  [ADDRESS_342725] substantiall y reduce the 
acquisition and transmission of HIV when applied to the gen ital or gastrointestinal mucosa. In 
addition to preventing HIV infection, topi[INVESTIGATOR_280925]: 
affordability and female control. Topi[INVESTIGATOR_280926]. Acceptability and utility of topi[INVESTIGATOR_280927]. For all dosing 
formulations, safety, stability, and ef ficacy must be established . 
 
Vaginal films are an attractive dosing option for several reasons. In terms of manufacturing, 
films are inexpensive, scalable, physically and chemically stable, uniform with regards to 
product content, and amenable to combinati ons of active ingredients. In terms of use, films are 
discreet, portable, and easy to store. Vaginal films can deliver fixed doses of microbicidal agents 
with minimal mess and without an applicator. The small volume of vaginal films may also result 
in less  dilution of endogenous antiviral or antibacterial properties of vaginal fluids compared to 
vaginal gels. In studies of spermicidal film, women have found vaginal films to be acceptable3-5. 
When Vaginal Contraceptiv e Film (VCF) was compared to foaming tablets containing 
nonoxynol -9 (N-9), contraceptive film was preferred in three different countries 3. Ninety -seven 
percent of 59 Mexican women, 60 percent of 52 Dominican women, and 86 percent of 51 
Kenyan women reported liking contraceptive film.  In particular, they c ited the following 
favorable characteristics:  ease of use , general feel or comfort, additional lubrication, and lack of 
side effects 3. Over e ighty percent of Cameroo nian sex workers, who participated in a large 
randomized placebo -controlled trial of N -[ADDRESS_342726] s once daily for 7 
consecutive days. The film and soft -gel capsule were chosen significantly more often than the 
tablet as the preferred dosage form (39%, 37% and 25%, respectively). In this particular study, 
film and soft gel were preferred because of faster dissolving time and easier insertion.7 In other 
studies, participants found v aginal films to be neater than foaming tablets and gel3,8.   
 
 
2.2 Integrated Preclinical/Clinical Program  
 
The Film Antiretroviral Microbicide Evaluation (FAME)  program b rings together an inter -
disciplinary group of research scientists from four academic institutions: University of Pi[INVESTIGATOR_9109], 
University of Washington, Carnegie Mellon University, [LOCATION_001] University  and the University of 
Colorado  The long term goal of the program is to  develop and evalu ate an extended delivery 
vaginal film containing an integrase inhibitor which could provide prot ection from HIV for one 
week or more following a single application. The first iteration of the FAME IPCP established 
proof of concept  that vaginal films containing the antiretrovirals (ARVs) dapi[INVESTIGATOR_280928] e ffectively as gel formulations  of those same ARVs . The 
FAME -[ADDRESS_342727] on the vaginal microenvironment.   Cervicovaginal lavage 
and vaginal fluid (as sampled by [CONTACT_280964], such as sponge  or wick) will be used to 
assess the impact of the film on the on the vaginal microbiota and glycome. The film’s impact on 
cellular immunity and inflammation will also be assessed, and the CVL samples will be 
assessed for changes to the innate anti -HIV activity. 
 
 
The film is intended to provide HIV protection for a week after a single application. 
Understanding how long the film remains in the vagina will be an integral part of this study. [CONTACT_281003]’s lab has developed an assay to detect the polymer Eud ragit® in cervical vaginal 
fluid. Genital samples from  Visit 1,  Visit 3 and Visit 4 will be evaluated for the presence of 
Eudragit.®.  Eudragit was chosen over the other polymers because of technical feasibility for the 
assay. The other polymers in the fi lm are cellulose based, and it would be very difficult to 
differentiate between the polymers in a biologic sample. Eudragit, on the other hand has a 
unique structure. Of note, all of the visible film will be removed with the CVL performed at Visit 
3; there fore, no Eudragit® should be detectable at Visit 4.  
   
This study has been designed to add to our knowledge about film application challenges. 
Product misplacement was noted in the three clinical trials of vaginal film previously conducted 
at the Universit y of Pi[INVESTIGATOR_9109]. While most participants could successfully insert the vaginal 
films, incorrect film placement was noted for some. In some instances, the vaginal film stuck to 
the finger after attempted insertion and in other instances the film was visuali zed on the external 
genitalia. Because the primary objective of this study is to assess safety and persistence, 
administration error will be noted immediately after the participant attempts to insert the film. If 
most the film is noted to be external to th e vaginal introitus, the film will be removed by [CONTACT_280965] a new vaginal film will be placed inside the vagina by [CONTACT_15370]. This will ensure 
the integrity of the primary objective.  
  
2.4 Safety Data: Placebo Film  
The placebo film consists of ingre dients  with a proven safety record .  Table  1 outlines  
documented usage with film excipi[INVESTIGATOR_280929] . 
 
FAME -101 version 1.0 20September2017   Page 14 Table 1: Placebo Film Excipi[INVESTIGATOR_280930]*  History of Vaginal Use  
Hydroxypropyl 
methyl cellulose 
(HPMC) or 
Hypromellose**, 
USP Film Forming Polymer  Vaginal; gel 3.5%  
Vaginal; tablet  5 mg  
Rectal; gel 4.35%  
(listed as 
hypromelloses**)  ESTRACE ® Cream and 
VAGIFEM® vaginal tablets, 
tenofovir and dapviri ne 
vaginal films  
Propylene glycol 
(PG), USP  Plasticizer/Dispersant  Vaginal; emulsion, 
cream 20%  
Vaginal; gel 3%  
Vaginal; suppository 
252 mg  VCF dissolving vaginal 
lubricant film (5%)35 
Hydroxyethyl 
cellulose, NF  Film Forming Polymer  Buccal  ; film 54.92 mg 
Oral; tablet, extended 
release 400mg  
Topi[INVESTIGATOR_2855]; gel 1.75%w/w  Tenofovir vaginal film, 
tenofovir and dapvirine 
vaginal gels  
Polyethylene glycol 
400, NF  Plasticizer/Dispersant  Rectal; suppository 
24.8%  
Topi[INVESTIGATOR_2855]; cream 1.5%w/w  
Topi[INVESTIGATOR_2855]; cream, 
emulsion, sustai ned 
release 7.5%w/w  Vaginal suppository  
Ammonio 
Methacrylate 
Copolymer Type B  
(Eudragit®), NF  Extended Release 
Polymer  Oral; capsule, extended 
release 35 .7mg  
Oral;tablet, extended 
release 11.05mg  
Tablet, film coated 8mg  * 
Hydroxypropyl 
cellulose, NF  Film Forming Polymer  Buccal; film 100.04mg  
Topi[INVESTIGATOR_2855]; patch  
Transdermal; film 
controlled release 19mg  
Oral; tablet 
(immed./comp. 
Release), film coated 
24mg  * 
  
*Although there is not a history of vaginal use, these excipi[INVESTIGATOR_280931] r pharmaceutical 
products such as buccal films, oral tablets, and in transdermal and topi[INVESTIGATOR_280932].  
 
Safety evaluation of the extended release placebo film was performed in a nonhuman primate 
model.  Six pi[INVESTIGATOR_280933], which is 
double the proposed human dosing (intended dosing is one film per week). In total, four films 
were delivered to each macaque over fourteen days. The vaginal microbiota, vaginal pH, and 
number of PMNs on gram stained v aginal smears were assessed before the first film placement 
and after the fourth film placement.  The integrity of the cervicovaginal tissues was assessed by 
[CONTACT_280966]. Of note, there was visible film in the vagina with each film 
placement. No adverse events were noted by [CONTACT_280967]; microbiota remained stable with no 
effect noted on the beneficial H202 producing microorganisms; vaginal pH remained within 
normal range; and PMN counts remained within the normal range even after more f requent 
administration than intended for use (Patton, personal communication) . The entire study report 
is presented in Appendix IV.  
 
Though the films used had different excipi[INVESTIGATOR_840], the tenofovir and dapi[INVESTIGATOR_280934] -[ADDRESS_342728] and no changes in the vaginal microenvironment noted. The 
macaque exposure model utilized for this protocol provided the initial assurances of safety for 
those studies a s well.  
FAME -101 version 1.0 20September2017   Page 15  
 
2.5 Summary  
It is appropriate to advance this placebo film  into a clinical trial for safety for the following 
reasons:  
• The individual ingredients used in  the film have a history of safe use in mucosal 
compartments (gastrointestinal and/or vaginal).  
• The same film was found to be safe in macaques without evidence of epi[INVESTIGATOR_280935], twice the frequency of intended human use.   
  
3 OBJECTIVES  
 
3.1 Primary Objectives  
 
o To assess the safe ty of a single dose of a placebo film whic h is intended for 
extended release of antiretroviral drugs  
 
3.2 Secondary Objectives  
 
• Acceptabilit y 
 
To describe the acceptability of the placebo vaginal film and how different qualities  
are associated with  higher or lower degrees of acceptability  
 
3.3 Explorator y Objectives  
 
• Vaginal Microenvironment  
 
o To compare the effects of the placebo film on the vaginal microbiota  and glycome 
pre and post study product use.   
 
• Persistence  
 
o To describe the persistence  of the placebo vaginal film  at 3, 7, [ADDRESS_342729]  
 
4.3 Description of Study Popu lation  
The study population will be HIV -uninfected women who meet criteria outlined in Section 5.  
 
4.4 Time to Complete Accrual  
Accrual is expected to be completed in approximately 6 months.  
 
FAME -101 version 1.0 20September2017   Page 16 4.5 Study Groups  
All participants will receive a single dose of the vagi nal film. They will be randomized at 
enrollment to the timing of Visit 3. In total , there will be four groups:  
 
• Visit 3 at Day 3 (range days 2-4) 
• Visit 3 at Day 7 (range days 6-8) 
• Visit 3 at Day 10 (range days 9-11) 
• Visit 3 at Day 1 4 (range days 12-16)  
 
4.6 Expected Duration of Participation  
The duration of study participation per woman is expected to be approximately 5-11 weeks . This 
includes the screening period.  
 
4.7 Site 
There is a single s tudy site : Magee -Womens  Hospi[INVESTIGATOR_307], Pi[INVESTIGATOR_9109], PA .   
 
 
[ADDRESS_342730].  
 
5.3 Retention  
Once a participant is enrolled , the study site will make every effort to retain her in follow -up to 
minimize possible bias associated with loss -to-follow -up. The site w ill implement the following 
procedures to enhance retention:    
 
• Thorough explanation of the study visit schedule and procedural requirements duri ng the 
informed consent process  and re -emphasis at each study visit.      
• Thorough explanation of the importan ce of all 4 study groups to the overall success of the 
study.  
• Collection of detailed locator information at the study screening visits, and active review and 
updating of this information at each subsequent visit.  
• Use of appropriate and timely visit reminde r mechanisms.  
• Immediate follow -up on missed visits.  
 
Study sites will use a participant tracking mechanism  to facilitate visit scheduling and timely 
identification and follow -up on missed visits.   
 
5.[ADDRESS_342731] meet all the following crit eria to be eligible for inclusion in the study:  
 
1) Age 18 through  45 years (inclusive) at screening  
 
2) Able and willing to provide written informed consent to be screened for and to take part in 
the study.  
FAME -101 version 1.0 20September2017   Page 17  
3) Able and willing to provide adequate locator informat ion  
 
4) HIV-uninfected based on testing performed by [CONTACT_280968] (per algorithm in 
Appendi x II) 
 
5) In general good health as determined by [CONTACT_7554]  
 
6) Agre e to be sexually abstinent for 48 hours prior to each visit  and from Visit 2 to seve n 
days after Visit 3   
 
7) At screening , agrees to abstain from any other intravaginal product or penetration 
(includi ng sex toys, excluding tampons) for 48 hours prior to each visit  and between Visit 2 
and 3 . 
 
8)  Willingness to undergo all study -related assess ments and follow all study -related 
procedures  
 
9) At screening and enrollment, agrees not to participate in other research studies involving 
drugs, medical devices, or vaginal products while enrolled in this trial  
 
5.[ADDRESS_342732] -menopausal women would introduce heterogeneity into the 
population.  
 
1.) Menopause (as defined as amenorrhea for one year or more without a n alternative 
etiology)  
 
2.) Hysterectomy  
 
3.) Participant report of any of the following:  
a) Known adverse  reaction to any of the study products (ever)  
b) Known adverse reaction to latex (ever)  
c) Non- therapeutic injection drug use in the 12 months prior to Screening  
d) Surgical procedure involving the pelvis in the 90 days prior to enrollment (includes 
dilation and c urettage or evacuation, and cryosurgery; does not include cervical 
biopsy for evaluation of an abnormal pap smear)   
e) Participation  in a drug, spermicide and/or microbicide study in the 30 days prior to 
enrol lment or anticipate d participation in an investig ational drug study until 
completion of the study  
f) Currently pregnant or p regnancy within 42 days prior to enrollment  
g) Currently lactating  
h) Use of a diaphragm, NuvaRing®, or spermicide for contraception  
i) Internal vaginal use of any device or product (except ta mpons) in the 48 hours  prior 
to enrol lment  
 
4.) Urogenital infection or suspected infection within 14 days of enrollment including: 
symptomatic cand idiasis, trichomonas vaginalis, and symptomatic bacterial vaginosis; or 
cervical infection, including N. gonorr hoeae (GC) , C. trachomatis  (CT), or mucopurulent 
cervicitis; syphilis; HSV lesions, or other sores ( Note: seropositiv e HSV without active 
lesions will not be excluded); acute pelvic inflammatory disease; urinary tract infection; 
recent exposure to a partne r with GC, CT, Trichomonas, syphilis, or NGU  
FAME -101 version 1.0 20September2017   Page 18  
5.) Antibiotic or antifungal therapy (vaginal or systemic) within 14 days  of enrollment  
 
6.) As determined by [CONTACT_978], has any significant uncontrolled active or chronic cardiovascular, 
renal, liver, hematologic, neurol ogic, gastrointestinal, psychiatric, endocrine, respi[INVESTIGATOR_696], 
immunologic disorder or infectious disease  
 
7.) Menses -like bleeding  at the time of the Enrollment visit * or expected menses -like bleeding 
within 14 days of the Enrollment visit  
(*Women who have vagi nal bleeding at the scheduled Enrollment Visit may return at a 
different date to be re -examined and possibly enrolled provided they are still within the 
screening window and meet all criteria.)  
 
8.) Any condition that, in the opi[INVESTIGATOR_689], would  preclude provision of consent, 
make participation in the study unsafe, complicate interpretation of study outcome data, or 
otherwise interfere with achieving the study objectives  
 
[ADDRESS_342733] Formulation    
A two inch by [CONTACT_280969] (2” x 2”) film containing no active pharmaceutical ingredient will be used. 
This placebo film is a cellulose based film containing hydroxypropyl methyl cellulose (HPMC) 
(E5 and K4M), hydroxyethyl cellulose (HEC), hydroxypropyl cel lulose (HPC), Eudragit® 
(Ammonio Methacrylate Copolymer Type B) , propylene glycol and polyethylene glycol 400.  
Placebo films will be manufactured by [CONTACT_280970].  
 
6.[ADDRESS_342734]  returns, destruction (if applicable) and other related issues as outl ined in 
instructions for DAIDS clinical trials. All unused study products must be returned to the 
Pharmacy .   
 
FAME -[ADDRESS_342735] has R&D 
stability for [ADDRESS_342736] Dispensing  
Study products will be dispense d only to enrolled participants  upon receipt of a written 
prescription signed by [CONTACT_237269].    
 
6.6 Concomitant Medications  
Enrolled  study participants may use concomitant medications during study participation.  Al l 
concomitant medications, over -the-counter preparations, vitamins and nutritional supplements, 
recreational drugs, and herbal preparations will be recorded on the concomitant medications  log 
form.   
 
All participants will be counseled to avoid the use of s permicide and other non -study vaginal 
products (other than tampons during menstruation and female condoms)  while participating in 
the study .  Participants who report use of these products will be counseled regarding the use of 
alternative methods, but repo rted use of these products does not require any change in study  
product administration or  follow -up procedures .  Condoms provided by [CONTACT_280971].   
 
7 STUDY PROCEDURES  
This section describes  visit-specific study  procedures.     
 
7.1 Pre-Screening   
As part of participant outreach and recruitment strategies, study staff may pre -screen potential 
study participants  (e.g. via telephone).  During these interactions, study staff may explain the 
study to participants and asce rtain elements of presumptive eligibility, to be confirmed at an on -
site screening visit. If the participant is eligible based on a screening script her name [CONTACT_280998].  If she signs consent, the telephone script wil l then 
become part of her research record . If she does not sign consent, the form will be de -identified . 
 
7.2 Visit 1: Screening Visit  
Screening may take place up to [ADDRESS_342737] at the Screening Visit.  
FAME -101 version 1.0 20September2017   Page 20  
 
   Table 2:  Visit 1 Procedures  
VISIT 1:  SCREENING VISIT  
Component  Procedure/Analysis  
 
 
 
 
 
 
 
ADMINISTRATIVE  • Written Informed Consent  
• Assign Study Number (PTID)  
• Review Eligibility  
• Collect Co ntact Information  
• Visit Questionnaire  
• HIV Pre -/Post -Test Counseling  
• Screening Results  
• Abstinence/Condom Counseling (& distribution prn)  
• Schedule Next Study Visit, prn  
• Participant Reimbursement  
 
URINE  • Pregnancy test  
• Urine dipstick, as clinically indicated  
SALIVA  • Rapid HIV  
BLOOD  • Confirmatory HIV, as clinically indicated  
 
VAGINAL  • pH 
• Wet Mount, as clinically indicated  
• Trichomonas (NAAT)  
• Future Use  
 
CERVICAL  • GC/CT (NAAT)  
• Future Use  
 
 
CVL • Levels of antiviral activity  
• Lectin microarray  
• Levels of glycoprotein s and mucins  
• Levels of cytokines & innate immunity factors  
• Eudragit® level  
 
 
PHYSICAL EXAM  
 • Physical Exam  
• Vital Signs (BP)  
• Height & Weight  
 
PELVIC EXAM  • Bimanual Exam, as clinically indicated  
• External Genital & Speculum Exam  
       
7.3  Visit 2: Enrollment  
Subjects who meet the inclusion and exclusion criteria following the Screening Visit may 
schedule an Enrollment Visit.  Care will be taken to schedule the  Enrollment visit at a time when 
the participant is not expecting to be actively bleeding or anticipati ng her menses within [ADDRESS_342738] of enrollment for this study.  Subjects with menses like  vaginal bleeding  at the 
Enrollment visit will not be randomized/enrolled  at that time.  These subjects  may be 
rescheduled if vaginal bleeding resolves before [ADDRESS_342739] of the vagina using a forcep s instrument. After film placement, 
participants will be scheduled for Visit 3. When Visit 3 occurs will be determined by 
[CONTACT_17628] (3,  7, 10 or 14  days).    
 
   Table 3:  Visit 2 Procedures  
VISIT 2:  ENROLLMENT – DAY 0 (Day [ADDRESS_342740] Use)  
Component  Procedure/Analysis  
 
 
 
ADMINISTRATIVE  • Review/Confirm Eligibility  
• Collect/Update Contact [CONTACT_7171]  
• Visit Questionnaire  
• Screening Results  
• Abstinence/Condom Counseling (& distribution prn)  
• Assess/Document Adverse Events  
• Schedule Next Study Visit  
• Participant Reimbursement  
ACCEPTABILITY  • Acceptability Questionnaire  
 
URINE  • Pregnancy test  
• Urine dipstick, as clinically indicated  
 
 
VAGINAL  • pH 
• Wet Mount, as clinically indicated  
• Gram Stain  
• Quantitative Vaginal Culture  
• Quantitative PCR for microbiota  
• Futu re Use  
 
CERVICAL  • Future Use  
 
 
PHYSICAL EXAM  
 • Physical Exam, as clinically indicated  
• Vital Signs (BP)  
 
PELVIC EXAM  • Bimanual Exam, as clinically indicated  
• External Genital & Speculum Exam  
• Post -insertion External Genital Exam  
• Repeat Speculum Exam, prn  
RAN DOMIZATION  • Randomization to timing of V3  
 
 
STUDY PRODUCT  • Study Product Distribution  
• Participant Self -Inserted (1st attempt)  
• Clinician -inserted (2nd attempt), prn  
 
FAME -101 version 1.0 20September2017   Page 22  
7.4 Visit 3: Follow -Up Visit  
The timing of Visit 3 will be determined through the randomizatio n process. All participants will 
be randomized to return either 3,7,10, or 14  days after f ilm insertion. Visit 3 procedures are 
outlined in Table 4.  The windows around these study visits are as follows:  
Day 3 ( days 2-4) 
Day 7 ( days 6-8) 
Day 10 ( days 9-11) 
Day 14 ( days 12-16)  
 
   Table 4:  Visit 3 Procedures  
VISIT 3:  FOLLOW -UP VISIT – 3, 7, 10, [ADDRESS_342741] FILM INSERTION  
Component  Procedure/Analysis  
 
 
ADMINISTRATIVE  • Collect/Update Contact [CONTACT_7171]  
• Visit Questionnaire  
• Abstinence/Condom Counseling (&  distribution prn)  
• Assess/Document Adverse Events  
• Schedule Next Study Visit  
• Participant Reimbursement  
ACCEPTABILITY  • Acceptability Questionnaire  
 
URINE  • Pregnancy test  
• Urine dipstick, as clinically indicated  
 
 
VAGINAL  • pH 
• Wet Mount, prn  
• Trichomonas (NAAT),  as clinically indicated  
• Gram Stain  
• Quantitative Vaginal Culture  
• Quantitative PCR for microbiota  
• Future Use  
 
CERVICAL  • GC/CT (NAAT), as clinically indicated  
• Future Use  
 
 
CVL • Levels of antiviral activity  
• Lectin microarray  
• Levels of glycoproteins and mucins  
• Levels of cytokines & innate immunity factors  
• Eudragit® level  
 
 
PHYSICAL EXAM  
 • Physical Exam, as clinically indicated  
• Vital Signs (BP)  
 
PELVIC EXAM  • Bimanual Exam, as clinically indicated  
• External Genital & Speculum Exam  
 
 
 
 
 
 
 
 
 
 
FAME -101 version 1.0 20September2017   Page 23 7.5 Visit 4: Follow -Up Vis it [ADDRESS_342742] Enrollment  
The final scheduled visit will be 21 (18 -25) days after the Enrollment Visit . 
 
   TABLE 5:  Visit 4 Procedures  
VISIT 4:  FOLLOW -UP VISIT  
Component  Procedure/Analysis  
 
 
ADMINISTRATIVE  • Collect/Update Contact [CONTACT_7171]  
• Visit Que stionnaire  
• Abstinence/Condom Counseling (& distribution prn)  
• Assess/Document Adverse Events  
• Participant Reimbursement  
ACCEPTABILITY  • Acceptability Questionnaire  
 
URINE  • Pregnancy test  
• Urine dipstick, as clinically indicated  
 
 
 
VAGINAL  • pH 
• Wet Mount, as cl inically indicated  
• Trichomonas (NAAT), as clinically indicated  
• Gram Stain  
• Quantitative Vaginal Culture  
• Quantitative PCR for microbiota  
• Future Use  
 
CERVICAL  • GC/CT (NAAT), as clinically indicated  
• Future Use  
 
 
CVL • Levels of antiviral activity  
• Lectin microar ray 
• Levels of glycoproteins and mucins  
• Levels of cytokines & innate immunity factors  
• Eudragit® level  
 
 
PHYSICAL EXAM  
 • Physical Exam, as clinically indicated  
• Vital Signs (BP)  
 
PELVIC EXAM  • Bimanual Exam, as clinically indicated  
• External Genital & Speculum Exam  
 
7.[ADDRESS_342743] study visit, and 
as clinically indicated . Participant s who become pregnant will be referred for care . Should the 
pregnancy be diagno sed during study follow -up, pelvic  exams will only be performed to evaluate 
a participant's reported symptom. No genital specimens will be collected in a pregnant 
participant.  
 
Of note,  the participant will be encouraged to continue in the study so that sa fety data might be 
collected. Participants who are pregnant at the final study visit will be contact[CONTACT_280972].  
 
7.7 Interim Visits  
Interim visits may be performed at any time during the study  (and stu dy procedures repeated as 
clinically indicated) , for the following or other reasons:  
 
• For administrative reasons , e.g., a participant may have questions for study staff, or may 
need to re -schedule a follow -up visit.  
FAME -101 version 1.0 20September2017   Page 24 • In response to AEs.  When interim contac ts or visits are completed in response to 
participant reports of AEs, study staff will assess the reported event clinically and 
provide or refer the particip ant to appropriate medical care.   
• In the event of laboratory processing issues (i.e. inconclusive STD testing, lost or 
inadequate sample  
• For other reasons at participant request.  
 
 Details of the interim visit will be recorded in the chart notes.  
 
7.8 Clinical Evaluations and Procedures  
Physical exams will include the following assessments:   
 
• Vital signs:  
o Blood pressure  
 
• Measurements of:  
o Weight  (at Screening only)  
o Height (at Screening only)  
  
• Focused physical exam (at Screening only) : 
o General  appearance  
o Cardiac exam   
o Respi[INVESTIGATOR_237245]   
o Abdomen   
 
Additional assessments may be performed at the discretion of  the examining clinician in 
response to symptoms or illnesses present at the time of the exam.  
 
7.[ADDRESS_342744]  
Wet mount if clinically indicated  
Vaginal pH  
Dipstick urinalys is 
Confirmatory HIV testing if indicated  
 
MWRI  Laboratories  
 
Cervical NAAT for chlamydia , gonorrhea  
Vaginal NAAT for trichomonas  
Vaginal Gram stain  
Quantitative vaginal cultures  
Quantitativ e PCR for selected microbiota  
Levels of cytokines and innate immun ity factors  from CVL 
Anti-viral activity from CVL  
 
[LOCATION_001] University Laboratory (Mahal) and/or MWRI Laboratory  
Levels of glycoproteins and mucin in CVL  
Lectin microarray in CVL  
 
 
University of Colorado Lab  
FAME -101 version 1.0 20September2017   Page 25 Eudragit®  levels in CVL and vaginal fluid   
 
7.[ADDRESS_342745] 
operating procedures for proper collection, processing, labeling, handling, transport, and 
storage of specimens.  In cases where la boratory results are not available due to administrative 
or laboratory error, sites are permitted to re -draw and/or re -collect specimens.  
 
7.[ADDRESS_342746] with 
conta minated needles, blood, and blood products, appropriate blood and secretion precautions 
will be employed by [CONTACT_43613][INVESTIGATOR_280936].  All biological s pecimens sent 
to the University of Colorado lab will be transported using packaging mandated by [CONTACT_44321] 42 Part 
72.  Biohazardous waste will be contained according to institutional, transportation/carrier, and 
all other applicable regulations.   
 
FAME -101 version 1.0 20September2017   Page 26 8 ASSESSMENT O F SAFETY  AND CLINICAL MANAGEMENT  
 
8.1 Safety Monitoring  
The study site investigators are responsible for continuous close safety monitoring of all study 
participants, and for alerting the Protocol Team if unexpected concerns arise. A sub -group of 
the Protocol Team, including the Protocol Chair or designee, the DA IDS Medical Officer, and 
the External Safety Monitor will serve as the Protocol Safety Review Team  (PSRT) . Close 
cooperation among the PSRT and the study site will be necessary to monitor participant sa fety 
and respond to occurrences of toxicity in a timely manner. Appropriate safety monitoring will be 
contingent upon excellent communication between study participants and study staff, and upon 
cooperation among study staff, investigators, the External Sa fety Monitor , and the DAIDS 
Medical Officer .  
 
8.[ADDRESS_342747] review of data and safety monitori ng.  This 
physician,  independent of the study sponsor , will be available to monitor data from this site.  
His/her minimum qua lifications  will include experience as a physician and experience in the 
conduct of clinical resear ch. This individual will not rec eive salary or other support from the 
grant.  The External (Independent)  Safety Monitor model has been used successfully for other 
Magee -Womens  Hospi[INVESTIGATOR_280937]. The proposed individual  will meet th e qualifications outlined above  and have training 
in the importance of the objective treatment of clinical safety data.   
 
The Data Management team for this site will generate data summaries for the Protocol Chair, 
the External Safety Monitor , and the DAIDS M edical Officer  on an at least  monthly basi s. More 
frequent ad hoc safety reviews can be implemented during the initial enrollment and throughout 
the study as needed. These data summaries will include adverse event, accrual and retention 
data. The External Safety Monitor  will evaluate adverse event data independently as well to 
determine whether the study protocol should continue as originally designed, should be 
changed, or should be terminated.   
 
Approximately once a month the PSRT will convene  via email or telephone to review adverse 
event data. Only masked safety data will be reviewed by [CONTACT_111153].  If more urgent safety 
matters arise , telephone  calls can occur more frequently.    
 
The IRB will be notified of any seriou s and unexpected adverse events  according to the policies 
outlined in the University of Pi[INVESTIGATOR_9109] I RB Policy and Procedure Manual9. 
 
The following information will be submitted to the University of Pi[INVESTIGATOR_280938] a research protocol , as required by [CONTACT_280973] : 
 
• The frequency of monitoring durin g the renewal interval, including the dates of data and 
safety monitoring;  
• A summary of any assessment performed to evaluate external factors or other relevant 
information that may have an impact on the safety of study volunteers or the ethics of 
the resea rch study;  
• A summary of the outcome of procedural reviews conducted to ensure subject privacy 
and research data con fidentiality;  
• Any conclusions regarding changes to the anticipated benefit -to-risk ratio of study 
participation and final recommendations rel ated to continuing, changing, or terminating 
the study, with accompanying rationales as appropriate.  
 
FAME -[ADDRESS_342748].  As such, an AE can be an unfavorable or 
unintended sign (including an abnormal laboratory finding, for example), symptom or disease 
temporally associated with t he use of an investigational product, whether or not considered 
related to the product.  This definition is applied to all groups beginning from the time of 
randomization.   
 
Study participants will be provided instructions for contact[CONTACT_280974], except for possible life -threatening events, 
for which they will be instructed to seek immediate emergency care.  Where feasible and 
medically appropriate, participants will be encouraged to see k evaluation at Magee -Womens  
Hospi[INVESTIGATOR_17399] l of UPMC , where the study clinician s are based, and to request that  a study  clinician be 
contact[CONTACT_18110].  All participants reporting a  clinically significant untoward medical 
occurrence will be followed either in person or by [CONTACT_237273] (returns to 
baseline) or stabilizes  over a four week period . 
 
Study site staff will document in source documents all AEs reported by [CONTACT_280975].   
 
For each study participant, AE documentation and reporting will be undertaken throughout the 
scheduled duration of follow -up, i.e., through Visit 4.  
 
The PI/designee will gra de the severity of each AE and the relationship of the AE to study 
product:   
 
AE severity will be graded per the DAIDS Table for Grading Adult and Pediatric Adverse Events, 
Version 2.1, July 2017  and the Female Genital Grading Table for Use in Microbicide Studies 
(Appendix 1 , version 1.0,  November 2007)  except tha t asymptomatic BV will not be considered 
an AE.  AEs not included in the Female Genital Grading Table will be graded by [CONTACT_280976] 2.1, July 2017 .  In cases where a genital AE is covered in both tables, 
the Female Genital Grading Table for Use in Microbicide Studies will be the grading scale 
utilized.   
 
The relationship of all reported AEs will be assessed based on the Manual for Expedited 
Report ing of Adverse Events to DAIDS  (Version 2.0, dated January 2010 ) and the clinical 
judgment of the PI/designee.   
 
Per the Manual for Expedited Reporting of Adverse Events to DAIDS, the relationship 
categories that will be used for this study are:  
Related : There is a reasonable possibility that the AE may be related t o the study agent(s)  
Not related : There is not a reasonable possibility that the AE is related to the study agent(s)  
The study products that must be considered when AE relationship s are assigned are the 
placebo film.   
 
The DAIDS Table for Grading Adult and Pediatric Adverse Events, the Female Genital Grading 
Table for Use in Microbicide Studies, and Version 2.0 of the Manual for Expedited Reporting of 
Adverse Events to DAIDS  are available on the DAIDS Regulatory Support Center (R SC) web 
site:   http://rs c.tech -res.com/  
 
All AE s will be captured on an AE log form.  The form should be  reviewed at each study visit  
and updated as needed.   For any serious or expedited AEs (SAEs/EAEs) that are continuing at 
FAME -101 version 1.0 20September2017   Page 28 a participant’s study exit visit, the  PI/designee must  establish a clinically appropriate follow -up 
plan for the AE  and review with the DAIDS Medical Officer .  At a minimum, the AE must be re -
assessed by [CONTACT_237275]  2 weeks  after the participant’s study exit visit  (Visit 4) ; additional 
evaluations al so may take place at the discretion of the PI/designee.  The same approach must 
be taken for any AEs deemed related to study product that are found to have increased in 
severity at the study exit visit  (Visit 4) .  For those AEs requiring re -assessment, if the AE has not 
resolved or stabilized at the time of re -assessment, study staff will continue to re -assess the 
participant at least once per month while the study is ongoing.  After the study has ended, all 
AEs requiring re -assessment will be re -assessed a t least once within the 30 -60 days after the 
study end date.   
 
8.4 Expedited Adverse Event Reporting Requirements  
8.4.1 Expedited Adverse Event Reporting to DAIDS  
Requirements, definitions and methods for expedited reporting of Adverse Events (AEs)  are 
outlin ed in Version 2.0 of the DAIDS EAE Manual, which is available on the DAIDS RSC  
website at http://rsc.tech -res.com/clinical -research -sites/safety -reporting/manual.  
 
The DAIDS Adverse Experience Reporting System (DAERS), an internet -based reporting 
system, m ust be used for expedited AE reporting to DAIDS. In the event of system outages or 
technical difficulties, expedited AEs may be submitted via the DAIDS EAE Form. This form is 
available on the DAIDS RSC website at http://rsc.tech -res.com/clinical -research -sites/safety -
reporting/daids/paper -eae-reporting .  
 
For questions about DAERS,  please contact [CONTACT_50787] 
[EMAIL_946] .  Please note that site queries may also be sent from within the 
DAERS application itself.   
 
For questions about expedited reporting, please contact [CONTACT_163409] 
(DAIDSRSCSafetyOffice@tech -res.com ).  
 
EAE reporting procedures specific to this protocol are that once the site has submitted EAEs via 
DAERS (as above), the RSC Safety Office will also prepare the  draft safety reports and send 
them to the DAIDS M edical Officers  for review.  The study site will be contact[CONTACT_280977] .  
 
For all EAEs submitted, sites must file an RSC update with the fi nal or stable outcome  
unless the initial EAE submitted had a final or stable outcome noted already.  
 
 
EAE Reporting Level  
This study uses SAE category of expedited AE reporting as defined in the DAIDS EAE Manual.   
 
Study Agents for Expedited Reporting to DAIDS  
The study agent  that must be considered in determining relationships of AEs requiring 
expedited reporting to DAIDS is the placebo film.  
 
Reporting Period  
AEs must be reported on an expedited basis during the entire study duration for an individual 
subject (from study enrollment until study completion or discontinuation of the subject from 
study participation for any reason) .  After the protocol -defined AE reporting period, unless 
otherwise noted, only suspected unexpected serious adverse reactions (S [LOCATION_003]Rs as defined in 
Version 2.0 of the EAE Manual) will be reported to DAIDS if the study staff become aware of the 
events on a passive basis (from publicly available information).  
 
FAME -[ADDRESS_342749] be reported to DAIDS as critical events. 
The following information about the critical event will be submitted to DAIDS MO and Clinical 
Operations Officer:  
 
A detailed description of the problem;  
Actions the study site is taking or plans to take to address the problem, such as suspending 
participant enrollment, termination of research, revising study protocol or informed consent 
documents, increasing monitoring of the study participant, etc. Any revisions to the study 
protocol and in formed consent must be reviewed and approved by [CONTACT_280978].  
 
Serious or continuing noncompliance and suspension/termination of IRB approval must be 
reported as critical events as well.  
 
 
8.[ADDRESS_342750] event or not.  
 
Adverse events will be elicited at each follow -up visit . Referral to appropriate care will be offered 
to participants as needed.  Vaginitis and some sexually transmitted infections can be treated in 
the study clinic. The PI/designee should manage STI/RTI per CDC guidelines, available at 
http://www.cdc.gov .  Observed single dose treatment should be provided whenev er possible.  
Vaginally applied medications should not be used if possible.  
 
8.5.[ADDRESS_342751].  
 
 
8.6 Criteria for Early Termination of Study Participation  
Participants may voluntarily withdraw from the study for any reason at any time.  The Site 
PI/designee also may withdraw participants from the study to protect their safety and/ or if they 
are unwilling or unable to comply with required study procedures . Participants also may be 
withdrawn if the study sponsors, government or regulatory authorities, including the Office of 
Human Research Protections (OHRP), or site IRBs/ECs termina te the study prior to its planned 
end date.  Every reasonable effort is made to complete a final evaluation of participants who 
withdraw or are withdrawn from the study prior to completing follow -up.  Study staff members 
will record the reason(s) for all w ithdrawals in participants’ study records.   
FAME -[ADDRESS_342752]. Pharmacokinetic measures will assess persistence following a single  
exposure .  
 
9.2 Samp le Size and Accrual  
The primary aim of the study is to assess the local and systemic safety of a single dose of 
placebo vaginal film. The primary endpoint is the proportion of participants who experience a 
Grade 2 or higher adverse event. The proposed tota l sample size is N=64 divided into 4 arms 
(placebo film with follow up at days 3, 7, 10, or 14 assigned at a 1:1:1:1 ratio ).  Based on 
previous studies of vaginal products conducted at the study site, the accrual of [ADDRESS_342753] two Grade 2 or 
higher Adverse Events. For a given arm, if the true rate of a given toxicity endpoint is 5%, 16 
women per arm provide 80% power to exclude toxicity endpoint rates greater than 27% (the 
probabili ty of observing zero or one event is less than 0.05 when the true rate is 27%).  
 
 
Table 6:  Power Calculations for FAME 101  
 
Event 
Rate  P(No events | 
n=16)  P(1 or more events | 
n=16)  P(2 or more events | n=16)  
1% 0.851  0.149  0.011  
5% 0.440  0.560  0.189  
10% 0.185  0.815  0.485  
15% 0.074  0.926  0.716  
20% 0.028  0.972  0.859  
25% 0.010  0.990  0.937  
27% 0.007  0.993  0.955  
30% 0.003  0.997  0.974  
35% 0.001  0.999  0.990  
 
 
In previous studies of two different placebo film products the combined frequency of Grade 2 or 
higher Adverse Events was 19%. Assuming a similar frequency in the current study, a sample 
size of 64 women will assure that a 95% confidence interval for the Grade 2 or higher Adverse 
Events rate has an upper limit of no greater than 30%.  
 
 
FAME -101 version 1.0 20September2017   Page 31 9.3 Study Endpo ints 
9.3.1 Primary Endpoint    
Grade 2 Adverse Events  
The safety/toxicity endpoint is clinical or laboratory evidence of a Grade 2 or higher  Adverse 
Event as defined by [CONTACT_280979], Version 
2.1, July 2017  and the Female Genital Grading Table for Use in Microbicide Studies (Appendix 
1 to the DAIDS Table for Grading Adult and Pediatric Adverse Events, (Dated November 2007 ). 
9.3.2 Secondary and Exploratory Endpoint s 
The secondary and exploratory endpoint s of this study are as follows:  
 
Secondary: Acceptability  
Reports of overall acceptability of the film and qualities of the experience with the film will be 
measured using a self -report survey drawing items from two sources. Overall acceptability is 
measured usin g standard language in market research methodology, each using a 5 -point 
agreement scale followed by [CONTACT_3440] -ended explanation. Assessment of film -specific qualities 
of the experience is assessed by a 9 -item scale drawn from previous research with particip ant-
inserted films. Questions assess perceptions of leaking, vaginal dryness, and sensation of the 
film inside the vagina during and after insertion.  
Exploratory: Vaginal Microenvironment  
Given that there is no non -product use arm, participants will serve as their own control. 
Assessment of baseline microenvironment will take place d uring the enrollment visit with the 
exception of CVL properties. CVL will be obtained at the screening visit so that the 
microenvironment  can recover prior to study product admi nistration at the enrollment visit.  
 
Levels of lectin binding  and mucins measured in CVL samples  
Endogenous and exogenous glycolytic enzymes, formulated microbicide products, and 
microbial flora interact with mucins and may alter their structure and funct ion. These alterations 
may be detected with lectins, which are sugar specific binding molecules, and can be bound to 
reporter molecules (such as horseradish peroxidase) in an ELISA type assay.   
 
Changes in the Glycome  
Lectin microarray will be used to asse ss changes in the glycome . 
 
Nugent Score  
Clinically significant changes in vaginal flora will be evaluated by a change in the Nugent score 
baseline (Visit 2, pre -exposure) to Visit 5.  The Nugent score is graded 1 to 10 as follows:  
Normal, 0 to 3  
Intermedi ate, 4 to 6  
BV, 7 -10 
 
Any shift from normal at baseline to intermediate or BV at Visit 3 or 4, or shift from intermediate 
or BV to normal at Visit 3 or 4 will be considered a scientifically  meaningful change in vaginal 
microbiota .   
 
Quantitative vaginal c ultures  and quantitative PCR  
Meaningful changes will be defined by [CONTACT_55559] 1 log changes in dominant 
members of the micro biota , including Lactobacillus  species, Gardnerella  vaginalis , key 
anaerobic  microorganisms , Enterococcus  species, Escherichia coli , Staphylococcus aureus , 
Group B Streptococcus , and Candida  species.  
 
Levels of anti -viral activity    in CVL  
In-vitro anti-HIV activity will be determined by [CONTACT_280980] -bl assay.  
FAME -101 version 1.0 20September2017   Page 32  
The TZM -bl assay will determine HIV -1 infection by [CONTACT_280981]. To 
assess the potency of the CVL, serial dilutions will be made and tested to determine the IC 50. 
 
Levels of cytokine and innate immunity factors  
Changes in cervical cytokine expression and innate immunity factors in cervicovag inal lavage  
will be assessed .  Changes within each group will be reported.  
Exploratory: Pharmacokinetic (PK) / Persistence of Eudragit®  in CVL  
Persistence of polymer  will be determined as detected levels of polymer  in va ginal fluid 
collected through cervic ovaginal lavage .  
 
9.4 Blinding  
All participants will receive a single dose of the vaginal film. They will be randomized to the 
timing of Visit 3. This will not be blinded.  
 
9.5 Random Assignment  
The randomization scheme will be generated and maintained by a membe r of the Data 
Management Division at the study site.  Women will be randomized to one of the four arms at a 
1:1:1:1 ratio using a permuted block design with random block sizes of 4 and 8.  In order to 
minimize bias in group assignment, participants will be  given study identification numbers.  A 
study staff member will allot the identification numbers in sequential order as participants 
become eligible to enroll in the study.  These numbers will be randomly assigned with timing of 
Visit 3. The randomization scheme will be created for a total of 72 participants; the overage will 
be created to compensate for participant withdrawals or unusable products.   
 
9.6 Data Monitoring and Analysis  
9.6.1 Data Monitoring  
This clinical trial will be conducted in compliance wit h the protocol, GCP guidelines, and 
applicable regulatory requirements.  All research charts are maintained in locked files in a 
locked room. The research staff, under the direction of the primary investigator, will create and 
maintain an electronic databa se on the hospi[INVESTIGATOR_280939]. The database will be backed up every night onto the 
server’s back -up system, and weekly onto an external storage device.  Appropriate firewall and 
virus sc anning software are installed and updated routinely by [CONTACT_5035][INVESTIGATOR_280940].  
 
This study will utilize electronic data capture.  Once the source documents are ready for 
computer entry, site staff will enter data into a data entry system.  Study data ma nagement staff 
will review the electronic data elements  for completeness and accuracy.  If there are any 
responses that are incomplete , unclear, or inconsistent with related data elements, the staff 
person will speak with the clinician in question as soon as possible to resolve the problem.  If 
necessary, the study staff  will ma ke the appropriate change in the electronic database which 
tracks time and date a change is made.   
 
9.6.[ADDRESS_342754] using frequencies, percent, and 95% confidence intervals. Individual participants 
will contribute once to the calculation of event rates.   
9.6.3 Secondary and Exploratory Endpoint Analysis  
Summary statistics of frequencies, percentages, and 95% confidence intervals will be provided 
for categorical data.  Means, standard deviations, medians, ranges and 95% confidence 
FAME -[ADDRESS_342755] analysis of variance (ANOVA) and Kruskal -Wallis tests will be used, where 
appropriate, to evaluate differences in the following continuous variables between the study 
arms: levels of glycoproteins and mucins i n CVL, levels of cytokines and innate immunity 
factors, and antiviral activity in CVL. Between groups, pre - to post -exposure changes in the 
above endpoints will also be evaluated using ANOVA and Kruskal -Wallis  tests, where 
appropriate, while paired Studen t’s t- and Wilcoxon signed -rank tests will be used to evaluate 
these changes within each study arm. Mixed effects l inear regression will be used to evaluate 
associations between days of exposure to study product and these outcomes.  
 
Nugent score will be c ategorized as follows: normal (score 0 -3), intermediate (score 4 -6), and 
bacterial vaginosis (score 7 -10). Differences in the categorized Nugent score pre and post 
exposure levels  will be evalu ated using Fisher’s exact , while McNemar’s tests will be used t o 
evaluate pre - to post -exposure shifts between normal (score 0 -3) and abnormal (score 4 -10) 
vaginal microflora within each study arm.  
 
Prevalence of microorganisms at each visit will be compared between the study arms using 
Fisher’s exact tests, while pr e- to post -exposure shifts will be evaluated within each group using 
McNemar’s tests. Differences between the study arms in the quantity of microorganisms at each 
visit, as well as the change in quantity, will be evaluated using Mann -Whitney U tests. 
Meani ngful changes will be defined by [CONTACT_280982] 1 log changes in dominant 
members of the microflora, including Lactobacillus (H2O2 positive and negative strains), 
anaerobic gram negative rods, Gardnerella vaginalis, Candida species, facultative gram 
negative rods, Streptococci and facultative gram positive cocci and rods. Fisher’s exact tests will 
be used to evaluate differences in these changes between study arms.   Mixed effects l inear 
regression (for continuous outcomes) and generalized estimat ing equations (for binary 
outcomes) will be used to evaluate associations between days of exposure to study product and 
these outcomes.  
 
 
Time since last menstrual period will be included as a potential confounder in these analyses.  
  
9.6.[ADDRESS_342756].  The intent -to-treat 
cohort (ITT) will be defined as those who were randomized .  The evaluable cohort (Eval) is a 
subs et of ITT  participants. Evaluable participants will be defined as participa nts who complete 
the Screening and Enrollment Visit s and return for the ir Visit [ADDRESS_342757] aced .   
 
Table 7: Statistical Analysis Plan  
Endpoint  Variable  Statistics  
Primary   
Adverse Events  Frequency, Percent, 95% 
Confidence Interval  
Exploratory   
Persistence of Eudragit®  in CVL  Frequency, Percent, 95% 
Confidence Interval  
Levels of glycoprotein s and mucins, 
in CVL  Mean, SD, Median, Range, 
95% Confidence Interval  
Antiviral activity in CVL  Mean, SD, Median, Range, 
95% Confidence Interval  
FAME -101 version 1.0 20September2017   Page 34  
Change in vaginal flora (Nugent 
score)  Frequency, Percent, 95% 
Confidence Interval  
 
 
Culture /qPCR result s from vaginal 
organisms  Frequency, Percent, 95% 
Confidence Interval  
Mean, SD, Median, Range, 
95% Confidence Interval  
 
Change  in cytokine  and innate 
immunity factors  Mean, SD, Median, Range, 
95% Confidence Interval  
Lectin Microarray to assess chang es 
in gylcome  Mean, SD, Median, Range, 
95% Confidence Interval  
[ADDRESS_342758].   
 
10.1.2 Children  
The NIH has mandated that children be included in research trials when appropriate.  This study 
will enroll women aged 18 to 20 who are able to give informed consent.  This study meets 
“Justifications for Exclusion” criteria for younger children as set forth by [CONTACT_18121].  Spe cifically, 
"the research topic to be studied is irrelevant to (young) children" and "a separate, age -specific 
study in (adolescent) children is warranted and preferable" at a later time . 
 
10.1.3 Prisoners  
Prisoners will not be included in t his study (for screening or enrollment).  Any participants 
incarcerated during the course of participation in the trial will not be followed during their 
incarceration, and will be discontinued from the study.  Participants who have been released 
from inca rceration will be permitted to return for any protocol specified follow -up or safety visits 
per the guidelines of the local IRB.  
 
10.1.[ADDRESS_342759] their willingness to continue 
study participation.   
 
10.2.1 Risk/Benefit Statement  
Risks  
It is not expected that this trial will expose human subjects to unreasonable risk.  The 
intervention used in this s tudy is unlikely to cause uncomfortable side effects and is only given 
once . However, there may be unknown risks or side effects associated with the use of the 
vaginal film.  Some women who used the film in other studies have reported vaginal discharge, 
and irritation and discomfort.   
 
Having genital exams may cause some discomfort from placing the speculum.  It is unlikely that 
collection of genital samples will cause discomfort.  Cervico vaginal lavage has been associated 
with mild discomfort secondary to  the introduction of sterile fluid in to the vagina and its removal.  
Standard study procedures do not include a blood draw; however, a blood draw is required if a 
confirmatory HIV test needs to be run. Phlebotomy may lead to discomfort, feelings of dizzines s 
or faintness, and/or bruising, swelling and/or infection.  
 
Disclosure of sexually transmitted infection (STI) may cause sadness or depression in 
volunteers.  Disclosure of HIV -positive status has been associated with depre ssion, suicidal 
ideation, and de nial as well as social isolation.  Participation in clinical research includes the 
risks of loss of confidentiality and discomfort with personal nature of questions.  
 
Benefits  
Participation in this trial likely will have no direct benefit to volunteers.  Some volunteers may 
have the opportunity to access expedient treatment and decreased morbidity due to e arly 
diagnosis and treatment of  a cervical and/or vaginal abnormality with expedient referral if an 
abnormality is detected.  Lastly, the participant may  appreciate the opportunity to contribute to 
the body of knowledge in the field of microbicide research.  However, there is no guarantee that 
volunteers will receive any of these benefits.  
 
10.3 Incentives  
Volunteers will not be charged for any of the study vis its, study supplies or examinations.  There 
are no costs to participants in this study other than their time.  Pending IRB approval of these 
compensation guidelines, women will be compensated for their time and inconvenience and for 
their travel needs whil e participating in the protocol.  The approved amounts of compensation 
will be given out at each visit.  The visits will be prorated and partial payment given in the event 
that the participant only completes a portion of the study visits.  The following pr oposed 
compensation amounts were created based on common institutional  practice for studies 
investigating vaginal products, as well as studies utilizing observation periods in the Clinical  
Translational Research Center.   
 
 Visit 1   $50 
FAME -101 version 1.0 20September2017   Page 36  Visit 2    $50 
 Visit 3   $100 (if evaluable and compliant with date/ time)  
 Visit 4    $[ADDRESS_342760] and 
Compliance Office, the Office of Human Research Protections, and/or the University of 
Pi[INVESTIGATOR_237251]’s health information.  Each member of the staff 
has log -on identification and password, logs off before leaving a computer screen unattended, 
and closes their office door when out of the office.  All research records will be kept for a 
minimum of seven  years following closure of th is study  (per University of Pi[INVESTIGATOR_280941]) .    
 
10.[ADDRESS_342761] may discontinue this study at 
any time.  Ongoing safety monitoring will track the incidence of AEs and EAEs.  In the event of 
an abnormal number of reported AEs and/or EAEs judged to be  related to study product  the 
External Safety Monitor  will contact [CONTACT_079] [INVESTIGATOR_280942] a temporary hold on 
further enrollment.  
[ADDRESS_342762] CONTAINMENT  
 
11.1 Laboratory Specimens  
Laboratory specimens will be handled in a manner consistent with institutional, OSHA, and GLP 
guidelines.  Study staff members are trained in the appropriate handling of laboratory 
specimens.  Samples such as urine that will be divided for multiple analyses will be divided 
according  to site SOP.  
   Table 8:  Laboratory Test Methods  
SAMPLE  METHOD  LABORATORY  
 
URINE  Pregnancy test  Clinical Research Center  
CLIA #39D1031322  Urine dipstick  
 
SALIVA  Rapid HIV  Clinical Research Center  
CLIA #39D1031322  
 
BLOOD  Confirmatory HIV  UPMC Presby[CONTACT_280983]# 39D0911193  
 
 
VAGINAL*  pH Clinical Research Center  
CLIA #39D1031322  Wet Mount  
Trichomonas (NAAT)   
Magee -Womens Research Institute  
CLIA #39D1004688  Gram Stain  
Quantitative Vaginal Culture  
Quantitative PCR for 
microbiota  
FAME -101 version 1.0 20September2017   Page 37  
CERVICAL*   
GC/CT (NAAT)  Magee -Womens Researc h Institute  
CLIA #39D1004688  
 
 
 
 
CVL Levels of antiviral activity  Magee -Womens Research Institute/Dezzutti 
Laboratory  
(non -diagnostic laboratory)  
Lectin microarray  Magee -Womens Research Institute/Moncla 
Laboratory  
(non -diagnostic laboratory) and/or  
[LOCATION_001] University (Mahal Laboratory)  Levels of glycoproteins and 
mucins  
Levels of cytokines & innate 
immunity factors  Magee -Womens Research Institute/Moncla 
Laboratory  
(non -diagnostic laboratory)  
Eudragit® level  University of Colorado  
(non -diagnosti c laboratory)  
      *Future Use Samples will be stored at Magee -Womens Research Institute; use and processing lab to 
be determined  
11.1.[ADDRESS_342763] 
infection  as clinically indicated .  Urine will be tested for HCG via the Sure -Vue® test. 
 
11.1.2 Vaginal Samples  
The assessment of vaginal flora will be based on the Nugent Scoring System for Gram Stained 
Vaginal Smears as well as assessment of several gro ups of organisms  by [CONTACT_280984] (culture) 
based methods .  In addition, selected microbiota will be detected using a quantitative 
polymerase chain reaction (qPCR) test which has been developed and validated within the 
laboratory.  Gram stained vaginal smear s will have neutrophils quantified according to site 
laboratory SOP.    Collection will be done as gently and carefully as possible so as to collect an 
adequate sample that is unlikely to disturb the mucosa or overall vaginal microenvironment .  
Trichomonas  vaginalis will be detected using an amplified DNA assay and handled according to 
policies outlined in SOPs for this study.  
11.1.3 Cervical Swabs  
C. trachomatis  and N. gonorrhoeae   will be detected using an amplified DNA assay and handled  
according to poli cies outlined in SOPs for this study.   
11.1.4 Cervicovaginal Lavage Samples  
Eudragit®  Content in CVL  
Aliquots of lavage samples will be tested for polymer  levels  (according to SOP).   
 
Anti-viral Activity in CVL  
Aliquots of lavage samples will be tested for anti -viral and antibacterial activity as  outlined in the 
site SOPs .  
 
Cervical Cytokines and Innate Factors  in CVL  
Cytokines (for example, IL -1β and TNFα) along with innate immune factors (for example, 
antiproteases) that could contribute to a proinflammatory milieu or changes in the glycomic 
signatures may be evaluated.”  
 
Glycome Studies  
Aliquots of lavage samples wil l be tested for glycoproteins, mucins and lectin microarray.   
 
 
FAME -[ADDRESS_342764] of Medical Mic robiology  (ABMM) , directs the Infectious Disease  
Research Laboratory at Magee -Womens Research Institute.  This laboratory is CLIA -inspected 
and maintains its own CLIA license.  Thus, all testing done in this research laboratory is 
performed with the same l evel of quality control as required in a licensed clinical laboratory.   
 
11.3 Specimen Storage and Possible Future Research Testing  
Part of the consent form will include an explanation of future use of vaginal and cervical 
specimens and blood samples.  Any future use or residual  samples will be stored at Magee -
Womens Research Institute, Microbiology Laboratory, 5th floor for an indefinite period of time.  
The principal investigator [INVESTIGATOR_280943].  
 
Any results from r esearch done on  future use or  leftover specimens will not be placed in health 
records and will be kept confidential . The language and format employed in the consent for 
these purposes are an IRB -approved means commonly employed in studies performed at this  
and other study sites within our institution to obtain permission for use of stored samples.  All 
primary study endpoints, protocol -specified testing, and QA/QC testing will be ascertained prior 
to any additional testing of stored specimens.   
 
11.[ADDRESS_342765] (IRB)/ethics committee (EC) and any other applicable regulatory entity (RE). Upon 
receiving final approval, the site will submit all required proto col registration documents to the 
DAIDS Protocol Registration Office (DAIDS PRO) at the Regulatory Support Center (RSC). The 
DAIDS PRO will review the submitted protocol registration packet to ensure that all of the 
required documents have been received.  
             
The site will receive an Initial Registration Notification when the DAIDS PRO receives a 
complete registration packet. Receipt of an Initial Registration Notification indicates successful 
completion of the protocol registration process. Sites will not receive any additional notifications 
from the DAIDS PRO for the initial protocol registration. A copy of the Initial Registration 
Notification should be retained in the site's regulatory files.  
 
Upon receiving final IRB/EC and any other applicable  RE approvals for an amendment, the site 
should implement the amendment immediately. The site is required to submit an amendment 
registration packet to the DAIDS PRO at the RSC. The DA IDS PRO will review the submitted 
protocol registration packet to ensure  that all the required documents have been received. The 
site will receive an Amendment Registration Site-specific ICF (s) WILL NOT be reviewed and 
approved by [CONTACT_280985] r eceives a complete registration packet  A copy of the Amendment 
Registration Notification should be retained in the site's regulatory files.  
 
FAME -[ADDRESS_342766] Development Inc., ([COMPANY_003], Wilmington, 
NC).  Site monitoring visits will be conducted to assess overall study compliance, as required 
per Requirements for On -Site Monitoring of DAIDS Funded and/or Sponsored Clinical Trials,  
GCP, and FDA regulations 21 CFR Part 312:  
 
http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/onsitemoni
tor_reqs.pdf   
 
Study mon itors will visit the site to complete the following:  
 
• Assess compliance with the study protocol, Good Clinical Practices (GCP) guidelines, 
and applicable regulatory requirements, including US CFR Title 45 Part 46 and Title 21 
Parts 50, 56, and  312 
• Review informed consent forms, procedures, and documentation  
• Perform data verification to ensure the accuracy and completeness of study data  as 
applicable  
• Verify proper collection and storage of biological specimens  
• Verify pr oper storage, dispensing,  and accountability for investigational study products  
• Assess implementation and documentation of internal site quality management 
procedures  
• Assess  site staff training needs  
 
Site investigators will allow study monitors to inspect study facilities and doc umentation (e.g., 
informed consent forms, clinic and laboratory records, other source documents, case report 
forms), as well as observe the performance of study procedures.  Investigators also will allow 
inspection of all study -related documentation by [CONTACT_280986], 
Sponsor and US regulatory authorities.  A site visit log will be maintained at the study sites to 
document all visits. The outcomes of the monitoring visits and the subsequent reports of 
resolutions of any identified p roblems will be provided to the Sponsor.  
 
 
12.4 Protocol Compliance  
All protocol amendments will be submitted to and approved by [CONTACT_32928][INVESTIGATOR_280944].  
 
12.5 Investigator’s Records  
The investigator wi ll maintain, and store securely, complete, accurate and current study records 
throughout the study.  Study records will not be destroyed prior to receiving approval for record 
destruction from the Principal Investigator [INVESTIGATOR_237256] a mi nimum of seven 
years following completion of the study, per the University of Pi[INVESTIGATOR_237257] .  Applicable 
records include source documents, site registration documents and reports, correspondence, 
informed consent forms, and notations of all contact s with the participant.   
FAME -[ADDRESS_342767] counseling.   
FAME -101 version 1.0 20September2017   Page 41  REFERENCES  
1. UNAIDS. Report on the global HIV/AIDS epi[INVESTIGATOR_901] 2008.  
2. UNAIDS. AIDS epi[INVESTIGATOR_280945]: November 2009.  
3. Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ. Cyanovirin -N potently 
inhibits huma n immunodeficiency virus type 1 infection in cellular and cervical explant models. J 
Gen Virol 2009;90:234 -43. 
4. Gupta P, Collins KB, Ratner D, et al. Memory CD4(+) T cells are the earliest detectable 
human immunodeficiency virus type 1 (HIV -1)-infected c ells in the female genital mucosal tissue 
during HIV -1 transmission in an organ culture system. J Virol 2002;76:[ADDRESS_342768]. Nat Med 
2000;6:475 -9. 
6. Cummins JE, Jr., Guarner J, Flowers L, et al. Preclinical testing of candidate topi[INVESTIGATOR_280946] -human immunodeficiency virus type 1 activity and tissue toxicity in a 
human cervical explan t culture. Antimicrob Agents Chemother 2007;51:1770 -9. 
7. Anton P, Elliott J, Tanner K, et al. Strong Suppression of HIV -1 Infection of Colorectal 
Explants following in vivo Rectal Application of UC781 Gel: A Novel Endpoint in a Phase I Trial. 
In: 16th Con ference on Retroviruses and Opportunistic Infections. Montreal; 2009.  
8. Anton P CR, Carballo -Diequez A, Kashuba A, Khanukhova E, Elliott J, Janocko L, 
Cumberland W, Mauck C, McGowan I. RMP -02/MTN -006: A Phase 1 Placebo -controlled Trial of 
Rectally Applied  1% Vaginal TFV Gel with Comparison to Oral TDF. 18th Conference on 
Retroviruses and Opportunistic Infections, [LOCATION_011] MA 2011.  
9. Steiner M, Spruyt A, Joanis C, et al. Acceptability of Spermicidal Film and Foaming 
Tablets Among Women in Three Countries. In ternational Family Planning Perspectives 
1995;21:104 -7. 
10. Visness CM, Ulin P, Pfannenschmidt S, Zekeng L. Views of Cameroonian sex workers 
on a woman -controlled method of contraception and disease protection. Int J STD AIDS 
1998;9:695 -9. 
11. Raymond E, A lvarado G, Ledesma L, et al. Acceptability of two spermicides in five 
countries. Contraception 1999;60:[ADDRESS_342769] Acceptability Study II (PAS II). In: International Partnership for 
Microbicides; 2009.  
13. Nel AM, Mitchnick LB, Risha P , Muungo LT, Norick PM. Acceptability of vaginal film, 
soft-gel capsule, and tablet as potential microbicide delivery methods among African women. J 
Womens Health (Larchmt) 2011;20:[ADDRESS_342770], Condon S, et al. Acceptability of five no noxynol -9 spermicides. 
Contraception 2005;71:[ADDRESS_342771] Manual. http://wwwirbpi[INVESTIGATOR_280947]/manual/.  
 
 
 
 
 
 
 
 
 
 
 
 
 
    
FAME -101 version 1.0 20September2017   Page 42 APPENDIX 1:  SCHEDULE OF STUDY VISITS AND PROCEDURES*  
Component  Procedure/Analysis  V1:  
Screening  V2:  
Enrollment  V3: 
3, 7, 10 
or 14 
Day FU  V4: 
21 
Day 
FU 
 
 
 
 
 
 
ADMINISTRATIVE  Written Informed Consent  X    
Assign Study Number (PTID)  X    
Review/Confirm Eligibility  X X   
Collect/Update Contact [CONTACT_7171]  X X X X 
Visit Questionnaire  X X X X 
HIV Pr e-/Post -Test Counseling  X    
Screening Results  X X   
Abstinence/Condom Counseling (& 
distribution prn)  X X X X 
Assess/Document Adverse Events   X X X 
Schedule Next Study Visit  X X X  
Participant Reimbursement  X X X X 
ACCEPTABILITY  Acceptability Q uestionnaire   X X X 
 
URINE  Pregnancy test  X X X X 
Urine dipstick  ^ ^ ^ ^ 
SALIVA  Rapid HIV  X    
BLOOD  Confirmatory HIV  ^    
 
 
VAGINAL  
(SWAB)  pH X X X X 
Wet Mount  ^ ^ ^ ^ 
Trichomonas (NAAT)  X  ^ ^ 
Gram Stain   X X X 
Quantitative Vaginal Culture   X X X 
Quantitative PCR for microbiota   X X X 
Future Use  X X X X 
 
CERVICAL  GC/CT (NAAT)  X  ^ ^ 
Future Use  X X X X 
 
 
CVL Levels of antiviral activity  X  X X 
Lectin microarray  X  X X 
Levels of glycoproteins and mucins  X  X X 
Levels of cytokines  & innate immunity 
factors  X  X X 
Eudragit® level  X  X X 
 
PHYSICAL  
EXAM  Physical Exam  X ^ ^ ^ 
Vital Signs (BP)  X X X X 
Height & Weight  X    
 
 
PELVIC  
EXAM  Bimanual Exam  ^ ^ ^ ^ 
External Genital & Speculum Exam  X X X X 
Post -insertion External Ge nital Exam   X   
Repeat Speculum Exam   ^   
RANDOMIZATION  Randomization to timing of V3   X   
 
STUDY  
PRODUCT  Study Product Distribution   X   
Participant Self -Inserted (1st attempt)   X   
Clinician -inserted (2nd attempt)   ^   
      X Required          ^ PRN/as clinically indicated  
*Safety Follow -up may extend beyond V4 to include AE Collection and any procedure deemed        
clinically indicated  
 
FAME -101 version 1.0 20September2017   Page 43  
 
 
APPENDIX II:  HIV TESTING AGORITHIM  
 
  START  
SAMPLE 1  
OraQUICK® Rapid 
HIV Test  IF 
NEGATIVE  
→ STOP  
REPORT AS HIV -
UNINFECTED; 
ENROLL IN STUDY  
   
IF POSITIVE    
 
   ↓  
REPORT AS 
INDETERMINATE,  
REQUIRES 
ADDITIONAL 
TESTING  IF  
INDET.  
← SAMPLE 2  
HIV Ab/Ag  Plasma 
Testing  IF 
NEGATIVE  
 
   
IF POSITIVE    
  ↓   
  REPORT AS HIV -
POSITIVE,  
REQUIRES 
CONFIRMATORY 
TESTING  
   
  ↓   
  REFERRALFOR 
CARE  
   
     
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FAME -101 version 1.0 20September2017   Page 44  APPENDIX  III: SAMPLE INFORMED CONSENT  
 
 
 
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY  
 
Title:   A Study of the Safety and Acceptability of a Placebo Vaginal Film  
Short Title:   FAME 101  
Consent Version :  0.7, 13September 2017    
 
Principal Investigators:  
Magee -Womens Hospi[INVESTIGATOR_280948]/GYN/RS  
Pi[INVESTIGATOR_9109], PA  [ZIP_CODE]  
Phone:  412 -641-5403  Katherine Bunge MD, MPH, Assistant [CONTACT_281004], PhD, Prof essor  
 
Reproductive ID Research Staff  [PHONE_5832]  
 
 
Funding Agency:   Division of AIDS, US National Institute of Allergy and Infectious Diseases, 
US National Institutes of Health  
 
You are being asked to take part in this research study because you are a woman between the 
ages of [ADDRESS_342772] 
being used in this study is a placebo (i.e. blank, inactive, no drug) vaginal film (similar to 
Listerine ® breath strips).  The person in charge o f this study is Katherine Bunge, MD .  Before 
you decide if you want to join this study, we want you to know about the study.  This consent 
form gives you information about this study.  The study staff will talk with you about it and 
answer your questions a bout this study.  You may decide to withdraw from the study at any 
time.   
 
YOUR PARTICIPATION IS VOLUNTARY  
Once you read, discuss, and understand the consent form, and if you agree to take part, you 
will be asked to sign your name [CONTACT_107517].  You will be offered a copy of this form to keep.  
 
 
PURPOSE OF THE STUDY  
This research study will involve the use of a placebo vaginal film.  Investigators want to evaluate 
the safety of the film and understand the acceptability and length of time for the film to dissolve 
once inserted into the vagina.  In future studies, this film may have medication added to it to 
deliver medication over an extended period of time (i.e. extended release).  
 
STUDY PRODUCTS  
This placebo film has not been used in humans before, but it is made from ingredients with a 
proven safety record.  The same film was found to be safe in monkey models.  
 
STUDY GROUPS   
All of the eligible women will be randomized (distributed by [CONTACT_3364], like rolling a dice) at the 
Enrollment Visit to one of four  study groups.  The groups will specify what day Visit [ADDRESS_342773]  Follow -up Schedule  # of participants  
[ADDRESS_342774] the same study visit schedule except for the timing of Visit 3.  All of the study 
groups are important to this study.   
 
FAME 101 STUDY PATICIPATION VISIT REQUIREMENTS  
 
Screening Vi sit: 
Your first visit will happen after you read, discuss, understand and sign this form.  The 
procedures done at this visit will take about an hour.  
Study staff will ask you where you live and other questions about you, your medical health 
(including wha t medications you are taking), menstrual history, your sexual practices and your 
understanding of the study requirements.   
Study staff will:  
Perform a physical exam, including height, weight and blood pressure.  
Talk with you about the requirements of the  study.  
Perform condom counseling and provide condoms if you need them.   
Test your urine  
A urine pregnancy test will be performed.  If you are pregnant you cannot join this study.   
If necessary, a urinalysis (urine dipstick) will be performed.  
Perform a rapid HIV test using blood or saliva.  
You will be told your HIV test result as soon as it is available, approximately 20 minutes.  You 
will talk with the study staff about the meaning of your result, how you feel about it, and ways to 
prevent HIV and oth er sexually transmitted infections.  Your sample will be tested for the 
antibody to HIV. An antibody is a substance that blood cells make to fight infection. Exposure 
(contact) to the HIV virus produces antibodies. Sometimes HIV test results are not clearl y 
positive, but also not clearly negative.  In that case, we will do more tests until we know your 
status for sure.  You must receive your HIV test results to be in the study.  If the test shows you 
have HIV, you cannot join the study.  We will refer you t o available sources of medical care and 
other services you may need.  Your partner(s) may have access to free HIV counseling and 
testing, if needed.   
Perform a pelvic examination:  
The study doctor or research clinician will use a speculum, a plastic or me tal instrument used to 
separate the walls of the vagina.  The study clinician will check your vagina and cervix for signs 
of infection, and other problems.  They will also take some fluids to test for sexually transmitted 
infections or diseases (commonly k nown as STIs or STDs, including gonorrhea, chlamydia, and 
trichomonas) and other possible problems if they feel it is necessary.  
The study clinician will perform a cervicovaginal lavage (CVL). This involves putting saline (salt 
water) into your vagina and  using a pi[INVESTIGATOR_8462] (or suction bulb) to draw up the fluid and wash the 
walls of your vagina and the cervix. The washing lasts for one minute. The purpose of collecting 
this lavage fluid is to use it to compare future fluid collected during the course of the study after 
you have been using the study product if you are enrolled into the study.  
FAME -[ADDRESS_342775] agree to periods of abstinence (no sex) during the study an d agree not to use vaginal 
products throughout the study.  The details will be discussed with you.   
 
If you are eligible and decide to enroll, the following may happen at every additional visit:  
Your contact [CONTACT_280987] a study questionnaire  
You will have your blood pressure taken and a urine pregnancy test performed  
A bimanual exam (to feel uterus and ovaries ) will be done as part of the pelvic exam only as 
clinically indicated  
A physical exam may be performed as needed  
You will be reminded of abstinence requirements and of the importance of not using other 
vaginal products throughout the study  
Condoms and pro tocol counseling will be reviewed; condoms will be provided if you need them  
The next study visit will be scheduled  
You will be provided of results of tests that would impact your care (i.e. STD testing results, 
results of evaluations as a result of vagina l complaints, pregnancy test results).  You will not be 
given the results of the tests that are done for research purposes (i.e. vaginal fluid and CVL).   
You may be offered treatment for infections diagnosed during the study or you will be referred 
for treatment  
 
Visit 2 (Enrollment; Day 0):   Duration of visit = approx. 1 ½ hours  
At this visit, you will:  
Answer acceptability questions related to the vaginal film.  
Have a pelvic examination, including a visual examination of the outside of your vagina, and a 
speculum examination.  The study clinician will check your vagina and cervix for signs of 
infection or any problems.  Vaginal and cervical fluids will be collected to test for bacteria, 
organisms and baseline tests.   If an infection is present  you may be offered treatment or 
referred for treatment as needed.  
If you are bleeding, the visit will need to be re -scheduled within 45 days of the screening.   
Be randomly assigned by [CONTACT_280988].   
The film will be obtained from t he pharmacy and given to you with verbal/written instructions on 
how to insert it.  A researcher will remain in the room, behind a curtain while you attempt to 
insert it in case you have questions and to time the insertion.  
Following insertion, the clinici an will do a quick look at the outside genital area to be sure she 
cannot see the film.    
   
If the film is seen outside or if you are unable to get the film in, a new film will be dispensed from 
the pharmacy and will be inserted by [CONTACT_19811] a s peculum.  
You will be asked to return for Visit 3 according to your randomized assignment.   
 
 
Visit 3 (Day 3, 7, 10 or 14)   Duration of visit = up to 45 minutes  
At this visit, you will:  
FAME -[ADDRESS_342776] a pe lvic examination performed by a study clinician that will include a check of the 
external genital area and vagina and cervix (using a speculum) for signs of an infection or 
problem.  Vaginal and cervical fluids will be collected to test for bacteria and or ganisms, 
changes that may have occurred during the use of study products and, if necessary, look for 
any other problems. A CVL wash will be repeated. This fluid will be used for additional testing of 
the effect of the study film.  
 
Visit 4 (Day 21)  Duration  of Visit = up to 45 minutes  
During this visit, you will:   
Answer acceptability questions related to the vaginal film.  
Have a pelvic examination including a visual examination of the outside of your vagina and a 
speculum examination.  The study clinician will check your vagina and cervix for signs of  
infection  or any problems.  Vaginal and cervical fluids will be collected to test for bacteria and 
organisms.  A CVL wash will be repeated. This fluid will be used for additional testing of the 
effect of the s tudy film.  
Your study participation will end at this visit.  
 
Interim Visits  
It may be necessary for additional visit(s) during your participation in this study to have any of 
the study procedures listed above repeated in the event of unforeseen or unantici pated 
abnormal results; difficulties in sample delivery, processing, or testing; and/or if you experience 
any vaginal symptoms.   Additional relevant testing may be done as determined by a study 
clinician (i.e. urine dip to test for infection, herpes cultur e, etc.).  
 
It may also be necessary for the study staff to call you after your last study visit if you have any 
side effects that need to be followed.  In the rare event you become pregnant while participating 
in the study, the study staff will refer you f or appropriate care.  The investigator would 
encourage you to stay in the study so that safety data could be collected.   Additional genital 
samples will not be collected and a pelvic exam will not be performed unless you are 
experie ncing vaginal symptoms t hat the investigator  feels needs to be evaluated.   Study staff 
would need to follow up with you by [CONTACT_280989].  
 
RISKS AND/OR DISCOMFORTS  
 
Blood draw  
You may have  excessive bleeding , discomfort,  dizziness , faint ing, a small blood clot, bruising , 
swelling or infection .  
 
Pelvic Exam and Sample Collection  
During pelvic exams and sample/ fluid collection, you may f eel discomfort or pressure in your 
vagina and/or pelvis.     
 
Vaginal Film  
The vaginal film may cause so me side effects.  We do not yet know all the side effects of the 
film.  Some, but not all women who used film in other studies have had:  
Discharge from the vagina  
Irritation and discomfort  
 
Discussing Sexual Practices, Being tested for STDs and Waiting for  Test Results  
FAME -101 version 1.0 20September2017   Page 48 You may become embarrassed and/or worried when discussing your sexual practices, ways to 
protect against HIV and other infections passed through sex, and your test results.  You may be 
worried while waiting for your test results.  If you have  HIV or other STDs, learning this could 
make you worried.  Trained study staff will help you deal with any feelings or questions you 
have.  Finding out your HIV status could also cause problems between you and your partner.  If 
you have any problems, study staff will talk with you and/or your partner to try to help resolve 
them.  
 
FAME -[ADDRESS_342777] exams  and HIV/STI testing as part of your participation in this study.  You may 
receive treatment for certain STIs as explained above or you will be referred for treatment.     
 
NEW INFORMATION  
You will be told any new information learned during this study that  might affect your willingness 
to stay in the study.   
 
STOPPI[INVESTIGATOR_280949]  
A study doctor may need to remove you from the study early without your permission if:  
The study is stopped or cancelled  
You are not able to keep appointm ents 
Other reasons that may prevent you from completing the study successfully  
Participants who withdraw or who are withdrawn from the study prior to completing follow up 
may be asked to complete a final study visit.   
 
COSTS TO YOU  
There is no cost to you  for study related visits, the vaginal film, physical examinations, 
laboratory tests or other study procedures.  Treatments available to you from the study site for 
infections passed through sex may be given at no cost to you or you may be referred for 
available treatment while you are in the study.  
 
REIMBURSEMENT  
You will receive compensation  for your time, effort, and travel at the end of each  study visit if all 
study procedures were completed.  
   Visit 1 (Screening):   $50 
   Visit 2  (Enrollment ):     $50 
   Visit 3  (Randomized Visit):      $100 (if compliant with appointment  day/time)  
   Visit 4  (Final Visit)  :  $[ADDRESS_342778] to you.   Parking passes  will be provided 
as needed.  
 
CONFIDENTIALITY  
Every effort will  be made to keep your information confidential.  However, it is not possible to 
guarantee confidentiality.  Your personal information may be disclosed if required by [CONTACT_2371].  The 
study staff may use your personal information to verify that you are not in any other research 
FAME -101 version 1.0 20September2017   Page 50 studies.  This includes studies conducted by [CONTACT_280990].  
Any publication of this study will not use your name [CONTACT_107005].  
 
Your records may be reviewed by:  
[CONTACT_4289], and/or contractors of NIH  
Study monitors  
University of Pi[INVESTIGATOR_280950], chlamydia, or HIV, the Commonwealth of Pennsylvania 
requires that your name [CONTACT_280999].  You may be 
contact[CONTACT_280991](s).  
 
The investigators may use or disclose, for purposes described above, identifiable information 
(which may include identifiable medical information) related to your being in this study for a 
minimum of 7 years and for as long (indefinite) as it may take to complete this study.  
 
A description of this clinical trial will be available on http://www.clinicaltrials.gov .. This website 
will not include information that can identify you. At most,  the website will include a summary of 
the results. You can search this website at any time.  
 
FUTURE USE OF STUDY SAMPLES   
By [CONTACT_4907], you allow the researchers to use any leftover study samples (i.e. 
vaginal swabs, cervical or vaginal fluid) -- identified only by [CONTACT_280992] – for 
future use on the female genital tract . and how the body responds  to infections .  You would not 
be told or learn of the results.  Your specimens  used in this research study may contribute to a 
new discovery or treatment.   In some instances, these discoveries or treatments may be of 
commercial value and may be sold, patented, or licensed by [CONTACT_280993][INVESTIGATOR_280951].   You will not retain 
any property rights nor will you share in any money that the investigators, the University of 
Pi[INVESTIGATOR_9109], or their agents may realize.  
 
RESEARCH -RELATED INJURY  
If you believe that the research procedures have resulted in an injur y to you, immediately 
contact [CONTACT_079] [INVESTIGATOR_280952].   Emergency 
medical treatment for injuries solely and directly related to your participation in this research 
study will be provided to you by [CONTACT_5035][INVESTIGATOR_280953].  Your insurance provider may be billed 
for the costs of this emergency treatment, but none of those costs will be charged directly to 
you.  If your research  related injury requires medical care beyond this emergency treatment, 
you will be respo nsible for the costs of this follow -up care.  At this time, there is no plan for any 
additional financial compensation.   The US National Institutes of Health (NIH) does not have a 
mechanism to provide compensation for research related injury.   
 
YOUR RIGHT S AS A RESEARCH PARTICIPANT/VOLUNTEER  
Taking part in this study is completely voluntary.  You may choose not to take part in this study 
or leave this study at any time.  If you choose not to participate or to leave the study, you will 
not lose the benefit of services to which you would otherwise be entitled at this clinic.  If you 
want the results of the study after the study is over, let the study staff members know.  
 
PROBLEMS OR QUESTIONS  
FAME -[ADDRESS_342779] Katherine Bunge, MD or the research  staff at (412) [ADDRESS_342780] the University of 
Pi[INVESTIGATOR_280954] [PHONE_5833] .   
 
VOLUNT ARY CONSENT  
The above information has been explained to me and all of my current questions have been 
answered.  I understand that I am encouraged to ask questions, voice concerns or complaints 
about any aspect of this research study during the course of th is study, and that such future 
questions, concerns or complaints will be answered by a qualified member of the research team 
or by [CONTACT_458] [INVESTIGATOR_280955].  I understand that I may always request 
that my questions, concerns or c omplaints be addressed by [CONTACT_079].   At any 
time I may also contact [CONTACT_132133], University of 
Pi[INVESTIGATOR_9109] (1 -[PHONE_2954]) to discuss problems, concerns and questions; obtain information; 
offer input; or discuss situations in the event that the research team is unavailable.  By [CONTACT_230350] I agree to participate in this research study for the purposes described above.  A copy 
of this consent form will be offered to me.  
 
 
__________________ _________________   
Printed Name [CONTACT_2385]    
 
 
___________________________________  ______________  ______________  
Participant Signature     [CONTACT_281000] (am/pm)  
 
 
 
 
CERTIFICATION OF INFORMED CONSENT:   I certify that I have explained the nature and 
purpos e of this research to the above individual and I have discussed the potential benefits and 
possible risks of study participation.  Any questions the individual has about this study have 
been answered, and we will always be available to address future quest ions as they arise.  I 
further certify that no research component of this protocol was begun until after this consent 
form was signed.  
 
 
________________________________________   ____________________  
Printed Name [CONTACT_281001]  
 
 
________________________________________   ____________________  
Signature [CONTACT_281002] -101 version 1.0 20September2017   Page 52 APPENDIX IV  
Study  summary  for F2‐5.1: Placebo  (Extended  release  film):  super‐dosing  SAFETY  STUDY  
 
 
Background : A vaginal  film platform  has been  designed  to provide  extended  release  of an API [CONTACT_46431]  (at least)  
seven  days.  The film is optimized  for Appearance,  Dissolution,  Disintegration  and Manufacturability.  Placebo  
films  with  excipi[INVESTIGATOR_280956]‐[ADDRESS_342781]  been  provided  for pre‐clinical  testing.  
Purpose : This safety  study  will assess  responses  in the cervicovaginal  environment  with  placebo  film “super‐ 
dosing.”  Rather  than  once  a week  dosing,  we will expose  macaques  to two films  per week  for two weeks.  
We will assess  the vaginal  microflora,  pH, PMN  influx,  and surface  tissues  after  four  film placements  over  two 
weeks.  Additionally,  we will detect  the level  of one of the film platform  polymers  using  PK analysis,  as an indicator  
of residual  film presence  on day 14 of the study.  
Design:  
 
 
 
Vaginal  Flora:  Two  Vaginal  swabs  (dacron)  collected  from  mid‐depth  vaginal  canal  and placed  in MaxV  
transporter  tubes  for overnight  delivery  to MWRI  (Pi[INVESTIGATOR_9109],  PA) for semi‐quantitative  microbiologic  
assessment.  
Vaginal  pH/smear:  Vaginal  pH: Dab head  of a Dacron  tipped  swab  onto  a pH indicator  strip  (resolution  0.5 pH 
units)  to document  vaginal  pH. Vaginal  smear‐Gram  stain:  Roll the Dacron  tipped  swab  of vaginal  exudate  on a 
glass  microscope  slide.  The smear  is air dried  and subsequently  Gram  stained  for identification  and 
quantification  of polymorphonuclear  cells . 
Colposcopy:  Colposcopy  to take  place  after  vaginal  secretion  collections.  If vaginal  exudate/product  remnant  
obscures  the cervix,  save  images  of the cervicovaginal  site prior  to clearing  out vaginal  exudate.  Then  clear  area  
and continue  with  colposcopy.  Note  observations  and document  with  digital  photography.  Adverse  findings  
include  any break  in the integrity  of the epi[INVESTIGATOR_280957],  deeply  erythematous  or friable  tissues,  and microulcers.  
Note:  Limited  colposcopic  exams  and photos  were  additionally  collected  just prior  to and immediately             after  
each  film placement.  Remnant  film product  was noted,  but not removed  at these  visits.  
FAME -101 version 1.0 20September2017   Page 53 CVL:  Collect  two 2mL  saline  CVLs:  (“‐1”) before  cleaning  the site for colposcopy  if necessary,  and again  (“‐2”) 
after conducting  colposcopy.  Split  the recovery  fluid  from  each  CVL into two cryovials  and freeze  (‐80C)  for 
future  PK analysis  [UCD].  
Film  placement:  Administer  test film to the vaginal  fornix.  
 
 
RESULTS  
 
 
 
Vaginal  Microflora:  
Placebo  Films  had no effect  on beneficial  (H2O2  producers)  microorganisms  after  repeated  exposures:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Shifts  in potentially  harmful  microorganisms  after  super‐dosing:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There  was a low prevalence  of E. coli and G. vaginalis  organi sms,  neither  of which  increased  after  film use. 
Other  potentially  deleterious  organisms  S. aureus  and enterococcus  were  not cultured  from  any specimens.  
Day 0 Day 3 Day 7 Day 10 Day 14 
Vaginal  Microflora  √ √ 
8 
7 
6 
5 
4 
3 
2 
1 
0 
DAY 0 DAY 14 
H2O2  +  Lactobacilli  H2O2  +  Viridans  
7 
6 
5 
4 
3 
2 
1 
0 
DAY 0 DAY 14 
G. vaginalis  E. coli Number  of macaques  with  
organism cultured  Number  of macaques  with  
organism cultured  
FAME -101 version 1.0 20September2017   Page 54 Prevalence  of each  microorganism  detected  in vaginal  swabs  remained  quite  stable  after  super‐dosing  with the 
placebo  film platform  for extended  release  API. 
 
 
Compi[INVESTIGATOR_280958]: Super -Dosing  Placebo 
for Extended Release API  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=7 macaques  
 
 
 
 
 
A data  table  displaying  semi‐quantitative  scores  for each  sample  is appended  under  Raw  Data.   Day 0 
Pre- 
Exposure   
Day 14 
H2O2 +  Lactobacilli  6 6 
H2O2 - Lactobacilli  1 1 
H2O2 +  Viridans  5 5 
H2O2 - Viridans  7 5 
G. vaginalis  1 1 
S. aureus  0 0 
coagulase -negative  Staph  6 5 
group  B Strep  0 0 
group  C Strep  0 0 
group  F Strep  1 0 
group  G Strep  0 0 
non-groupable Beta -Strep  0 0 
diptheroids  7 7 
E. coli  2 0 
enterococcus  0 0 
black  anaerobic Gram  Negative Rods  7 7 
non-pi[INVESTIGATOR_280959]  7 7 
other  anaerobic GNR  0 0 
micrococcus  0 0 
proteus  0 0 
bacillus  0 0 
aerobic  Gram -positive rods  6 5 
aerobic  Gram -positive cocci  1 2 
 
FAME -101 version 1.0 20September2017   Page 55  
 
 
 
Vaginal  PMN  response  after  cumulative  exposures  to the extended  release  Film  Platform  (as noted  by [CONTACT_280994]):  
Gram  stained  vaginal  smears  were  assessed  for presence  of red blood  cells  (RBC)  and polymorphonuclear  cells  
(PMN)  as indicators  of a white  blood  cell infiltrate.  RBC are generally  associated  with  menses.  In a population  of 
[ADDRESS_342782]  calculated  a normal  range  of PMNs  to fall between  0 and 15 PMNs  
per high power  field  (unpublished).  This normal  range  appears  lightly  shaded  in the line graph  below.  
The graph  below  plots  the mean  values  (from  5 high  power  non‐adjacent  fields)  of PMN  counts  for each  macaque  
at baseline  and on day 14. Both  of the macaques  with elevated  PMN  counts  on Day 0 were  menstruating,  as was 
T02319  on Day 14. Clearly  this film platform  does  not elicit  a PMN  response  even  when  administered  more  
frequently  than  intended.  Raw  data  is appended.  
 
 
 
PMN  counts:  PLACEBO  FILM  
40 
 
35 
 
30 
 
25 
 
20 
 
15 
 
10 Normal  range  
5 
 
0 
Day 0 Day 14 
A07101  A10010  A10200  K05007  T02319  W04064  Z08187  
Day 0 Day 3 Day 7 Day 10 Day 14 
Vaginal  fluid  PMNs  √ √ 
FAME -[ADDRESS_342783]  on vaginal  pH, 
which  normally  measures  5.0‐8.5 in pi[INVESTIGATOR_280960].  Of four  samples  that measured  pH 7.0 or higher  in this 
study,  three  were  collected  during  menses.  
 
 
 
 
 
 
 
The weight  and temperature  of each  animal  also remained  within  normal  ranges.  No indication  of adverse  
health  responses  to multiple  film exposures  were  noted.  Vaginal  pH: PLACEBO  FILM  
9 
 
8.5 
 
8 
 
7.5 
 
7 
 
6.5 
 
6 
 
5.5 
 
5 
 
4.5 
 
4 
D0 D14 
A07101  A10010  A10200  K05007  T02319  W04064  Z08187  
Day 0 Day 3 Day 7 Day 10 Day 14 
Vaginal  pH √ √ 
FAME -101 version 1.0 20September2017   Page 57  
 
 
 
Cervicovaginal  Lavage  samples  were  stored  at ‐80oC in the Patton  Laboratory,  then  shipped  to UC Denver  (Core  
C). They  will be assessed  by [CONTACT_280995] a marker  for film presence  in the macaque  
vagina.  Optimizing  the conditions  for PK detection  of the polymer  will allow  future  studies  to include  drug  
deposition  and film platform  presence  to be distinguished  from  each  other.  
Two  CVL samples  were collected  from  each  macaque  on study  day 14. One (CVL‐1) was collected  prior  to clearing  
residual  film for colposcopy;  the second  (CVL‐2) was collected  after  removing  residual  film product.  In addition  to 
CVL,  a sample  of residual  film from  two macaques  was frozen  and provided  to the PK lab. 
The data  from  these samples  will be reported  separately,  and are not expected  to impact  the safety  findings.  
Day 0 Day 3 Day 7 Day 10 Day 14 
Cervicovaginal  Lavage  (PK) √ 
FAME -101 version 1.0 20September2017   Page 58  
 
 
 
Colposcopy  No adverse  findings  were  noted  by [CONTACT_280967].  Residual  film was frequently  noted.  When  an 
animal  was menstruating,  the residual  took  on a brown  to red tone  as seen  in photos.  Otherwise  the residual  
appeared  white.  No formulation  induced  changes  to the cervicovaginal  tissues  were  noted.  
 
 
Colposcopy  photo  plates  follow.  
Day 0 Day 3 Day 7 Day 10 Day 14 
Colposc opy √ √ √ √ √ 
F2‐5.1  Extended  Release  Film  Platform:  Super  Dosing  Safety  Study  
Framed  
photos  
indicate  time  
points  when  
specimens  
were  
collected.  M :Menses   
 
 
 
 
A07101  
 
Prior  to 
Film  
Placement  
 
 
Film  
placed  Film  1 
 
 
 
 
 
 
M Film  2 Film  3 Film  4 
 
 
 
 
 
A10010  
 
Prior  to 
Film  
placement  
 
 
Film  
placed  Baseline  
appearance  
(menses)  Residual  film 
appears  white  
+ menses  Residual  film 
+ exudate  Residual  film 
+ exudate  Residual  film 
+ exudate  
 
 
 
Baseline  appearance.  
Edema  Some  residual  
film noted  in 
exudate  Focal  
erythema  
(normal  near  
menses),  
Residual  film Residual  film 
+ menses  Residual  film 
+ exudate  Day 0 Day 3 Day 7 Day 10 Day 14 
M 
M 

F2‐5.1  Extended  Release  Film  Platform:  Super  Dosing  Safety  Study  
Framed  
photos  
indicate  time  
points  when  
specimens  
were  
collected.  M :Menses   
  
 
 
A10200  
 
Prior  to 
Film  
placeme nt 
 
 
 
Film  
placed  Film  1 Film  2 Film  3 Film  4 
 
 
Baseline  appearance  
 
K05007  
 
Prior  to 
Film  
Placement  
 
 
Film  
placed  Residual  film 
appears  white  Residual  film + 
menses  Residual  film 
post‐menses  Residual  film 
 
 
 
Baseline  appearanc e Residual  film 
appears  
white/yellow  Residual  film 
(suspected  
end of 
menses)  Residual  film Residual  film 
+ exudate  Day 0 Day 3 Day 7 Day 10 Day 14 
M 

F2‐5.1  Extended  Release  Film  Platform:  Super  Dosing  Safety  Study  
Framed  
photos  
indicate  time  
points  when  
specimens  
were  
collected.  M :Menses   
 
 
 
 
T02319  
 
Prior  to 
Film  
placement  
 
 
Film  
placed  Film  1 Film  2 Film  3 Film  4 
 
 
 
 
 
 
W04064  
 
Prior  to 
Film  
placement  
 
 
 
Film  
placed  Baseline  
appearance  Residual  film is 
white & 
original  shape  Residual  film is 
white.  
Petechiae  Residual  film 
appears  white  Residual  film 
+ menses  
 
 
Baseline  appearance  
(menses)  Residual  film 
appears  white. 
Focal  erythema.  Residual  film Residual  film Residual  film 
in pi[INVESTIGATOR_280961] 0 Day 3 Day 7 Day 10 Day 14 
M 
M 

F2‐5.1  Extended  Release  Film  Platform:  Super  Dosing  Safety  Study   
  
 
 
Z08187  
 
Prior  to 
Film  
Placement  Film  1 Film  2 Film  3 Film  4 
 
 
Film  
placed  
 
 
 
Baseline  appearance.  
Edema  Residual  film 
appears  white  
+ exudate  Residual  film Residual  film Residual  film 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Framed  photos  
indicate  time  
points  when  
specimens  
were  collected.  Day 0 Day 3 Day 7 Day 10 Day 14 

 
 Raw  data  
Vaginal  Flora:  Semi‐quantitative  results  (0‐4, denoting  organism  growth  on quadrants  of a plate)  were  reported  for 
each  organism  listed.  
 
 
 
 
 
 
N=7 Mn  A0710 1 A10010  A10200  K05007  T02319  W04064  Z08487  
Day 
0 Day 
14 Day 
0 Day 
14 Day 
0 Day 
14 Day 
0 Day 
14 Day 
0 Day 
14 Day 
0 Day 
14 Day 
0 Day 
14 
H2O2 +  Lactobacilli  1 1 4 1 1 3 3 4 0 0 3 4 1 1 
H2O2 - Lactobacilli  0 3 0 0 0 0 2 0 0 0 0 0 0 0 
H2O2 +  Viridans  2 4 2 2 4 4 0 0 0 0 3 4 3 4 
H2O2 - Viridans  3 2 4 0 2 3 3 0 4 3 3 4 3 4 
G. vaginalis  0 0 0 0 0 0 4 4 0 0 0 0 0 0 
S. aureus  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
coagulase -negative  
Staph  2 0 2 2 0 2 2 3 4 2 3 0 2 3 
group B Strep  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
group C Strep  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
group F Strep  0 0 0 0 0 0 0 0 0 0 3 0 0 0 
group G Strep  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
non-groupable  Beta- 
Strep  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
diptheroids  3 4 4 4 4 4 3 1 4 4 3 4 3 4 
E. coli  0 0 0 0 0 0 3 0 0 0 2 0 0 0 
enterococcus  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
black  anaerobic  
Gram  Negative Rods  3 4 4 4 4 4 3 4 4 4 4 4 3 4 
non-pi[INVESTIGATOR_280962]  2 4 4 4 3 4 4 4 3 4 4 4 3 4 
other  anaerobic GNR  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
micrococcus  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
proteus 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
bacillus  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
aerobic Gram - 
positive  rods 3 4 3 4 4 2 0 0 4 4 3 0 2 3 
aerobic Gram - 
positive cocci  0 4 0 0 0 0 0 0 0 0 3 0 0 2 
 
 
FAME 101 -version 1.0 64  20Sep17  Vaginal  pH: Vaginal  fluid  transferred  to pH indicator  strips  (resolution  0.5 pH units)  by [CONTACT_280996].  pH 
measures  are noted  for Day 0 and Day 14. 
 
Vaginal  pH D0 D14 
A07101  7.5*  6.5 
A10010  5.5 6.5 
A10200  6.5 7.5 
K05007  6.5 6.5 
T02319  6 7* 
W04064  7* 6.5 
Z08187  6.5 6.5 
*menses  
 
 
Gram  stain  PMN  count  from  vaginal  smear:  Polymorphonuclear  (PMN)  cells  were  counted  in 5 representative  
non‐adjacent  high  power  fields.  Presence  of red blood  cells  (RBC)  was also noted.  
 
 Polymorphonuclear  (PMN)  Cell Counts   
Animal  
ID Study  
Day Field  1 Field  2 Field  3 Field  4 Field  5 Total  Avg RBC  
Comments  
A07101  0 10 14 15 9 7 55 11 4 Macaque  menstruating  
14 1 3 0 0 0 4 0.8 0  
A10010  0 1 1 1 1 1 5 1 0  
14 0 0 0 0 0 0 0 0  
A10200  0 0 0 0 0 3 3 0.6 0  
14 0 0 0 0 0 0 0 0  
K05007  0 0 1 0 1 1 3 0.6 0  
14 0 0 0 0 0 0 0 0  
T02319  0 0 0 0 0 0 0 0 0  
14 2 1 5 1 1 10 2 0 Macaque  menstruating  
 
W04064  0 22 32 30 20 30 134 26.8  0 Macaque  menstruating;  
WBC  seen  in cervical  mucus  
14 0 0 0 0 0 0 0 0  
Z08187  0 2 1 1 0 0 4 0.8 0  
14 4 3 0 0 0 7 1.4 0  
RBC   0 = none  
1+ =less  than  one per field  
2+ =1‐4 per field  
3+ =5‐30 per field  
4+ = greater  than  30 per field  
 
FAME 101 -version 1.0 65  20Sep17  CVL:  Fourteen  frozen  samples  (2/macaque  on Day 14) were  batch  shipped  to PK lab at UC Denver.  (11/14/2017)  
 
 
Colposcopy:  Colposcopy  was conducted  prior  to each  film administration,  and on stud y day 14. Common  
findings  include  edema,  erythema,  petechiae  and ecchymoses.  These  are routinely  noted  in cycling  macaques  
regardless  of vaginal  product  use. In this study,  tissue  edema  and erythema  were  noted  by [CONTACT_280997]  (0, 25%.  50%,  75% or 100%).  Petechiae  and ecchymoses  were  noted  if present.  Adverse  findings  would  
include  any break  in the integrity  of the epi[INVESTIGATOR_280957],  deeply  erythematous  or friable  tissues,  and 
micro‐ulcers.  No adverse  findings  were  noted  in this study.  The raw colposcopic  data  is compi[INVESTIGATOR_280963].  
 
 
FAME 101 -version 1.0 66  20Sep17  
 
 
 
FAME 101 -version 1.0 67  20Sep17  1. UNAIDS. Report on the global HIV/AIDS epi[INVESTIGATOR_901] 2008.  
2. UNAIDS. AIDS epi[INVESTIGATOR_280945]: November 2009.  
3. Steiner M, Spruyt A, Joanis C, et al. Acceptability of Spermicidal Film and Foaming Tablets 
Among Women in Three Countries. International Family Planning Perspectives 1995;21:104 -7. 
4. Visness CM, Ulin P, Pfannenschmidt S, Zekeng L. Views of Cameroonian s ex workers on a 
woman -controlled method of contraception and disease protection. Int J STD AIDS 1998;9:695 -9. 
5. Raymond E, Alvarado G, Ledesma L, et al. Acceptability of two spermicides in five countries. 
Contraception 1999;60:[ADDRESS_342784] Acceptability Study II (PAS II). International Partnership for 
Microbicides; 2009.  
7. Nel AM, Mitchnick LB, Risha P, Muungo LT, Norick PM. Acceptability of vaginal film, soft -
gel capsule, and tablet as potential microbicide delivery methods among Afric an women. J Womens 
Health (Larchmt) 2011;20:[ADDRESS_342785], Condon S, et al. Acceptability of five nonoxynol -9 spermicides. 
Contraception 2005;71:[ADDRESS_342786] Manual. http://wwwirbpi[INVESTIGATOR_280947]/manual/ . 
 